Anti-CD74 antibodies, conjugates and uses thereof

Anti-CD74 antibodies with specific CDR sequences offer a targeted and less toxic method to reduce hematopoietic cells, addressing the toxicity issues of current transplantation regimens and minimizing adverse effects on non-targeted tissues.

WO2025250969A1PCT designated stage Publication Date: 2025-12-04VERTEX PHARMACEUTICALS INC
View PDF 74 Cites 0 Cited by

Patent Information

Application Number
PCT/US2025/031700
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-04-11
Filing Date
2025-05-30
Publication Date
2025-12-04

AI Technical Summary

Technical Problem

Current hematopoietic cell transplantation conditioning regimens are highly toxic and cause life-threatening complications due to their adverse effects on multiple organ systems and non-targeted cells, necessitating the development of less toxic therapies that can selectively reduce endogenous hematopoietic cell populations while minimizing impact on non-targeted tissues.

Method used

Development of anti-CD74 antibodies that bind specifically to human CD74, which are fully human or humanized, with specific amino acid sequences for their heavy and light chain complementarity-determining regions (CDRs), allowing for targeted reduction of hematopoietic cells.

Benefits of technology

The anti-CD74 antibodies provide a targeted approach to reduce hematopoietic cell populations with minimal toxicity to non-targeted cells and tissues, reducing the risk of relapse and adverse reactions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2025031700_04122025_PF_FP_ABST
    Figure US2025031700_04122025_PF_FP_ABST
Patent Text Reader

Abstract

The disclosure provides anti-CD74 antibodies, anti-CD74 antibody conjugates, compositions, and their use in reducing a population of hematopoietic cells.
Need to check novelty before this filing date? Find Prior Art

Description

Attorney Docket No.01245-0062-00PCT ANTI-CD74 ANTIBODY COMPOSITIONS AND METHODS CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of priority of US Provisional Application Nos. 63 / 654,412, filed May 31, 2024, and 63 / 787,525, filed April 11, 2025, each of which is incorporated by reference herein in its entirety for any purpose. REFERENCE TO ELECTRONIC SEQUENCE LISTING

[0002] The application contains a Sequence Listing which has been submitted electronically in .XML format and is hereby incorporated by reference in its entirety. Said .XML copy, created on May 27, 2025, is named “01245-0062-61US.xml” and is 678,549 bytes in size. The sequence listing contained in this .XML file is part of the specification and is hereby incorporated by reference herein in its entirety. FIELD

[0003] Anti-CD74 antibodies and anti-CD74 antibody conjugates are provided, as well as their use in conditioning hemopoietic stem cells. BACKGROUND

[0004] Hematopoietic cell transplantation is the administration of hematopoietic stem and progenitor cells to patients with a variety of acquired and inherited malignant and non- malignant disorders to establish marrow and immune function. Hematologic malignancies and non-malignant disorders are currently treated with high dose or lethal chemotherapy and / or radiation therapy conditioning regimens that are highly toxic to multiple organ systems, hematopoietic and non-hematopoietic cells, and the hematopoietic microenvironment prior to hematopoietic cell transplantation. These harsh conditioning regimens effectively kill the host subject's immune and niche cells and oftentimes adversely affect multiple organ systems, that may lead to life-threatening complications.

[0005] There is a need for the development of conditioning regimens that avoid undesirable toxicity, minimize the incidence of serious adverse reactions, and reduce a patient’s risk of relapse. There is also a need for therapies that can selectively reduce an endogenous hematopoietic cell population in a target tissue, while minimizing or eliminating the effects of such therapies on non-targeted cells and tissues. Attorney Docket No.01245-0062-00PCT SUMMARY

[0006] In some embodiments, an isolated anti-CD74 antibody is provided. Such isolated anti-CD74 antibody binds to human CD74, wherein the antibody is optionally fully human or humanized.

[0007] Accordingly, the following non-limiting embodiments are provided. Embodiment 1. An isolated antibody that binds human CD74, the antibody comprising: i) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 2; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 3; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 4; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 5; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 6; or ii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 101; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 102; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 103; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 104; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 105; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 106; or iii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 201; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 202; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 203; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 204; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 205; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 206; or iv) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 301; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 302; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 303; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 304; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 305; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 306; or v) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 501; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 502; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 503; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 504; (e) LCDR2 comprising the amino acidAttorney Docket No.01245-0062-00PCT sequence of SEQ ID NO: 505; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 506; or vi) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 601; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 602; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 603; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 604; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 605; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 606; or vii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 701; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 702; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 703; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 704; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 705; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 706; or viii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 801; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 802; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 803; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 804; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 805; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 806; or ix) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 901; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 902; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 903; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 904; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 905; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 906; or x) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1001; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1002; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1003; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1004; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1005; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1006; or xi) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1101; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1102; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1103; (d) LCDR1Attorney Docket No.01245-0062-00PCT comprising the amino acid sequence of SEQ ID NO: 1104; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1105; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1106; or xii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1201; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1202; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1203; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1204; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1205; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1206; or xiii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1301; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1302; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1303; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1304; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1305; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1306; or xiv) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1401; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1402; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1403; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1404; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1405; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1406; or xv) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1501; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1502; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1503; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1504; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1505; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1506; or xvi) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1601; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1602; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1603; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1604; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1605; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1606; or xvii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1701; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1702; (c) HCDR3Attorney Docket No.01245-0062-00PCT comprising the amino acid sequence of SEQ ID NO: 1703; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1704; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1705; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1706; or xviii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1801; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1802; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1803; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1804; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1805; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1806. Embodiment 2. An isolated antibody that binds human CD74, the antibody comprising: i) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 2 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 2 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 3 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 3 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 4 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 4 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 5 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 5 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 6 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 6 with one or two amino acid substitutions; or ii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 101 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 101 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 102 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 102 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 103 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 103 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 104 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 104 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO:Attorney Docket No.01245-0062-00PCT 105 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 105 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 106 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 106 with one or two amino acid substitutions; or iii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 201 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 201 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 202 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 202 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 203 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 203 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 204 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 204 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 205 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 205 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 206 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 206 with one or two amino acid substitutions; or iv) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 301 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 301 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 302 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 302 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 303 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 303 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 304 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 304 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 305 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 305 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 306 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 306 with one or two amino acid substitutions; or v) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 501 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 501 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ IDAttorney Docket No.01245-0062-00PCT NO: 502 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 502 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 503 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 503 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 504 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 504 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 505 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 505 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 506 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 506 with one or two amino acid substitutions; or vi) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 601 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 601 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 602 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 602 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 603 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 603 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 604 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 604 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 605 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 605 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 606 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 606 with one or two amino acid substitutions; or vii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 701 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 701 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 702 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 702 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 703 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 703 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 704 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 704 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO:Attorney Docket No.01245-0062-00PCT 705 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 705 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 706 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 706 with one or two amino acid substitutions; or viii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 801 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 801 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 802 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 802 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 803 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 803 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 804 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 804 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 805 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 805 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 806 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 806 with one or two amino acid substitutions; or ix) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 901 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 901 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 902 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 902 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 903 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 903 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 904 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 904 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 905 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 905 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 906 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 906 with one or two amino acid substitutions; or x) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1001 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1001 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ IDAttorney Docket No.01245-0062-00PCT NO: 1002 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1002 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1003 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1003 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1004 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1004 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1005 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1005 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1006 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1006 with one or two amino acid substitutions; or xi) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1101 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1101 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1102 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1102 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1103 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1103 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1104 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1104 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1105 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1105 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1106 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1106 with one or two amino acid substitutions; or xii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1201 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1201 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1202 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1202 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1203 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1203 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1204 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1204 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO:Attorney Docket No.01245-0062-00PCT 1205 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1205 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1206 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1206 with one or two amino acid substitutions; or xiii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1301 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1301 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1302 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1302 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1303 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1303 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1304 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1304 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1305 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1305 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1306 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1306 with one or two amino acid substitutions; or xiv) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1401 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1401 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1402 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1402 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1403 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1403 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1404 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1404 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1405 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1405 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1406 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1406 with one or two amino acid substitutions; or xv) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1501 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1501 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ IDAttorney Docket No.01245-0062-00PCT NO: 1502 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1502 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1503 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1503 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1504 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1504 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1505 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1505 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1506 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1506 with one or two amino acid substitutions; or xvi) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1601 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1601 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1602 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1602 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1603 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1603 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1604 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1604 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1605 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1605 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1606 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1606 with one or two amino acid substitutions; or xvii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1701 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1701 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1702 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1702 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1703 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1703 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1704 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1704 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ IDAttorney Docket No.01245-0062-00PCT NO: 1705 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1705 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1706 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1706 with one or two amino acid substitutions; or xviii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1801 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1801 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1802 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1802 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1803 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1803 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1804 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1804 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1805 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1805 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1806 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1806 with one or two amino acid substitutions. Embodiment 3. The isolated antibody of embodiment 1 or embodiment 2, wherein the antibody comprises: i) the CDRs of embodiment 1.i) and further comprises a heavy chain variable region (VH) that is at least 90% identical to the amino acid sequence of SEQ ID NO: 12; or ii) the CDRs of embodiment 1.ii) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 112; or iii) the CDRs of embodiment 1.iii) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 212; or iv) the CDRs of embodiment 1.iv) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 312; or v) the CDRs of embodiment 1.v) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 512; or vi) the CDRs of embodiment 1.vi) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 612; or vii) the CDRs of embodiment 1.vii) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 712; orAttorney Docket No.01245-0062-00PCT viii) the CDRs of embodiment 1.viii) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 812; or ix) the CDRs of embodiment 1.ix) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 912; or x) the CDRs of embodiment 1.x) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1012; or xi) the CDRs of embodiment 1.xi) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1112; or xii) the CDRs of embodiment 1.xii) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1212; or xiii) the CDRs of embodiment 1.xiii) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1312; or xiv) the CDRs of embodiment 1.xiv) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1412; or xv) the CDRs of embodiment 1.xv) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1512; or xvi) the CDRs of embodiment 1.xvi) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1612; or xvii) the CDRs of embodiment 1.xvii) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1712; or xviii) the CDRs of embodiment 1.xviii) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1812. Embodiment 4. The isolated antibody of any one of claims 1-3, wherein the antibody comprises: i) the CDRs of embodiment 1.i) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 12; or ii) the CDRs of embodiment 1.ii) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 112; or iii) the CDRs of embodiment 1.iii) and further comprises a comprising the amino acid sequence of SEQ ID NO: 212; or iv) the CDRs of embodiment 1.iv) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 312; or v) the CDRs of embodiment 1.v) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 512; orAttorney Docket No.01245-0062-00PCT vi) the CDRs of embodiment 1.vi) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 612; or vii) the CDRs of embodiment 1.vii) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 712; or viii) the CDRs of embodiment 1.viii) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 812; or ix) the CDRs of embodiment 1.ix) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 912; or x) the CDRs of embodiment 1.x) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 1012; or xi) the CDRs of embodiment 1.xi) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 1112; or xii) the CDRs of embodiment 1.xii) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 1212; or xiii) the CDRs of embodiment 1.xiii) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 1312; or xiv) the CDRs of embodiment 1.xiv) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 1412; or xv) the CDRs of embodiment 1.xv) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 1512; or xvi) the CDRs of embodiment 1.xvi) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 1612; or xvii) the CDRs of embodiment 1.xvii) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 1712; or xviii) the CDRs of embodiment 1.xviii) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 1812. Embodiment 5. The isolated antibody of any one of embodiments 1-4, wherein the antibody comprises: i) the CDRs of embodiment 1.i) and further comprises a light chain variable region (VL) that is at least 90% identical to the amino acid sequence of SEQ ID NO: 18; or ii) the CDRs of embodiment 1.ii) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 118; orAttorney Docket No.01245-0062-00PCT iii) the CDRs of embodiment 1.iii) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 218; or iv) the CDRs of embodiment 1.iv) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 318; or v) the CDRs of embodiment 1.v) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 518; or vi) the CDRs of embodiment 1.vi) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 618; or vii) the CDRs of embodiment 1.vii) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 718; or viii) the CDRs of embodiment 1.viii) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 818; or ix) the CDRs of embodiment 1.ix) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 918; or x) the CDRs of embodiment 1.x) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1018; or xi) the CDRs of embodiment 1.xi) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1118; or xii) the CDRs of embodiment 1.xii) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1218; or xiii) the CDRs of embodiment 1.xiii) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1318; or xiv) the CDRs of embodiment 1.xiv) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1418; or xv) the CDRs of embodiment 1.xv) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1518; or xvi) the CDRs of embodiment 1.xvi) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1618; or xvii) the CDRs of embodiment 1.xvii) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1718; or xviii) the CDRs of embodiment 1.xviii) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1818. Embodiment 6. The isolated antibody of any one of embodiments 1-5, wherein the antibody comprises:Attorney Docket No.01245-0062-00PCT i) the CDRs of embodiment 1.i) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 18; or ii) the CDRs of embodiment 1.ii) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 118; or iii) the CDRs of embodiment 1.iii) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 218; or iv) the CDRs of embodiment 1.iv) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 318; or v) the CDRs of embodiment 1.v) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 518; or vi) the CDRs of embodiment 1.vi) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 618; or vii) the CDRs of embodiment 1.vii) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 718; or viii) the CDRs of embodiment 1.viii) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 818; or ix) the CDRs of embodiment 1.ix) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 918; or x) the CDRs of embodiment 1.x) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 1018; or xi) the CDRs of embodiment 1.xi) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 1118; or xii) the CDRs of embodiment 1.xii) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 1218; or xiii) the CDRs of embodiment 1.xiii) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 1318; or xiv) the CDRs of embodiment 1.xiv) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 1418; or xv) the CDRs of embodiment 1.xv) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 1518; or xvi) the CDRs of embodiment 1.xvi) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 1618; or xvii) the CDRs of embodiment 1.xvii) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 1718; orAttorney Docket No.01245-0062-00PCT xviii) the CDRs of embodiment 1.xviii) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 1818. Embodiment 7. The isolated antibody of any one of embodiments 1-6, wherein the antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein: i) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 12 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 18; or ii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 112 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 118; or iii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 212 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 218; or iv) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 312 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 318; or v) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 512 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 518; or vi) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 612 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 618; or vii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 712 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 718; or viii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 812 and the VL isAttorney Docket No.01245-0062-00PCT at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 818; or ix) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 912 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 918; or x) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1012 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1018; or xi) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1112 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1118; or xii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1212 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1218; or xiii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1312 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1318; or xiv) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1412 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1418; or xv) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1512 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1518; or xvi) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1612 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1618; orAttorney Docket No.01245-0062-00PCT xvii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1712 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1718; or xviii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1812 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1818. Embodiment 8. The isolated antibody of any one of embodiments 1-7, wherein the antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein: i) the VH comprises the amino acid sequence of SEQ ID NO: 12 and the VL comprises the amino acid sequence of SEQ ID NO: 18; or ii) the VH comprises the amino acid sequence of SEQ ID NO: 112 and the VL comprises the amino acid sequence of SEQ ID NO: 118; or iii) the VH comprises the amino acid sequence of SEQ ID NO: 212 and the VL comprises the amino acid sequence of SEQ ID NO: 218; or iv) the VH comprises the amino acid sequence of SEQ ID NO: 312 and the VL comprises the amino acid sequence of SEQ ID NO: 318; or v) the VH comprises the amino acid sequence of SEQ ID NO: 512 and the VL comprises the amino acid sequence of SEQ ID NO: 518; or vi) the VH comprises the amino acid sequence of SEQ ID NO: 612 and the VL comprises the amino acid sequence of SEQ ID NO: 618; or vii) the VH comprises the amino acid sequence of SEQ ID NO: 712 and the VL comprises the amino acid sequence of SEQ ID NO: 718; or viii) the VH comprises the amino acid sequence of SEQ ID NO: 812 and the VL comprises the amino acid sequence of SEQ ID NO: 818; or ix) the VH comprises the amino acid sequence of SEQ ID NO: 912 and the VL comprises the amino acid sequence of SEQ ID NO: 918; or x) the VH comprises the amino acid sequence of SEQ ID NO: 1012 and the VL comprises the amino acid sequence of SEQ ID NO: 1018; or xi) the VH comprises the amino acid sequence of SEQ ID NO: 1112 and the VL comprises the amino acid sequence of SEQ ID NO: 1118; or xii) the VH comprises the amino acid sequence of SEQ ID NO: 1212 and the VL comprises the amino acid sequence of SEQ ID NO: 1218; orAttorney Docket No.01245-0062-00PCT xiii) the VH comprises the amino acid sequence of SEQ ID NO: 1312 and the VL comprises the amino acid sequence of SEQ ID NO: 1318; or xiv) the VH comprises the amino acid sequence of SEQ ID NO: 1412 and the VL comprises the amino acid sequence of SEQ ID NO: 1418; or xv) the VH comprises the amino acid sequence of SEQ ID NO: 1512 and the VL comprises the amino acid sequence of SEQ ID NO: 1518; or xvi) the VH comprises the amino acid sequence of SEQ ID NO: 1612 and the VL comprises the amino acid sequence of SEQ ID NO: 1618; or xvii) the VH comprises the amino acid sequence of SEQ ID NO: 1712 and the VL comprises the amino acid sequence of SEQ ID NO: 1718; or xviii) the VH comprises the amino acid sequence of SEQ ID NO: 1812 and the VL comprises the amino acid sequence of SEQ ID NO: 1818. Embodiment 9. An isolated antibody that binds human CD74, wherein the antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein: i) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 12 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 18; or ii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 112 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 118; or iii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 212 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 218; or iv) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 312 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 318; or v) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 512 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 518; orAttorney Docket No.01245-0062-00PCT vi) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 612 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 618; or vii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 712 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 718; or viii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 812 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 818; or ix) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 912 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 918; or x) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1012 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1018; or xi) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1112 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1118; or xii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1212 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1218; or xiii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1312 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1318; or xiv) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1412 and theAttorney Docket No.01245-0062-00PCT VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1418; or xv) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1512 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1518; or xvi) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1612 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1618; or xvii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1712 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1718; or xviii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1812 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1818. Embodiment 10. The isolated antibody of embodiment 9, wherein the antibody comprises: i) the VH and VL of embodiment 8.i and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 2; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 3; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 4; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 5; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 6; or ii) the VH and VL of embodiment 8.ii and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 101; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 102; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 103; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 104; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 105; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 106; or iii) the VH and VL of embodiment 8.iii and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 201; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 202; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 203; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 204; (e)Attorney Docket No.01245-0062-00PCT LCDR2 comprising the amino acid sequence of SEQ ID NO: 205; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 206; or iv) the VH and VL of embodiment 8.iv and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 301; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 302; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 303; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 304; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 305; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 306; or v) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 512 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 518; or vi) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 612 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 618; or vii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 712 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 718; or viii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 812 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 818; or ix) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 912 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 918; or x) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1012 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1018; or xi) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1112 and the VL is atAttorney Docket No.01245-0062-00PCT least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1118; or xii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1212 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1218; or xiii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1312 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1318; or xiv) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1412 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1418; or xv) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1512 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1518; or xvi) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1612 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1618; or xvii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1712 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1718; or xviii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1812 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1818. Embodiment 11. The isolated antibody of embodiment 9 or embodiment 10, wherein the VH comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to an amino acid sequence chosen from any one of SEQ ID NOs: 12, 112, 212, 312, 512, 612, 712, 812, 912, 1012, 1112, 1212, 1312, 1412, 1512, 1612, 1712, or 1812.Attorney Docket No.01245-0062-00PCT Embodiment 12. The isolated antibody of any one of embodiments 9-11, wherein the VL comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to an amino acid sequence chosen from any one of SEQ ID NOs: 18, 118, 218, 318, 518, 618, 718, 818, 918, 1018, 1118, 1218, 1318, 1418, 1518, 1618, 1718, or 1818. Embodiment 13. The isolated antibody of any one of the preceding embodiments, wherein the antibody is a monoclonal antibody. Embodiment 14. The isolated antibody of any one of the preceding embodiments, wherein the antibody is an antibody fragment. Embodiment 15. The isolated antibody of embodiment 14, wherein the fragment is a Fab, Fab’, Fv, scFv or (Fab’)2. Embodiment 16. The isolated antibody of any one of embodiments 1-13, wherein the antibody is a full-length antibody. Embodiment 17. The isolated antibody of any one of embodiments 1-13, wherein an Fc region of the antibody comprises IgG1, IgG2, IgG3, or IgG4. Embodiment 18. The isolated antibody of any one of embodiments 1-13, wherein the antibody comprises a human IgG1 heavy chain constant region. Embodiment 19. The isolated antibody of any one of embodiments 1-13, wherein the antibody comprises a human IgG4 heavy chain constant region. Embodiment 20. The isolated antibody of embodiment 18, wherein the antibody comprises a mutant human IgG1 heavy chain constant region. Embodiment 21. The isolated antibody of embodiment 20, wherein the mutant IgG1 heavy chain constant region comprises a mutation selected from a substitution at L234, a substitution at L235, a substitution at P329, or a combination thereof, according to EU numbering. Embodiment 22. The isolated antibody of embodiment 21, wherein the mutant IgG1 heavy chain constant region comprises an L234A substitution, an L234A substitution, and a P329A substitution or a combination thereof, according to EU numbering. Embodiment 23. The isolated antibody of any one of embodiments 20-22, wherein the mutant IgG1 heavy chain constant region comprises a deletion of K447, according to EU numbering. Embodiment 24. The isolated antibody of any one of embodiments 20-23, wherein the mutant IgG heavy chain constant region comprises a substitution at S239, according to EU numbering.Attorney Docket No.01245-0062-00PCT Embodiment 25. The isolated antibody of any one of embodiments 20-24, wherein the mutant IgG heavy chain constant region comprises an S239C substitution, according to EU numbering. Embodiment 26. The isolated antibody of any one of embodiments 1-13 and 16-25, wherein the antibody comprises a human IgG kappa light chain constant region. Embodiment 27. The isolated antibody of any one of embodiments 1-26, further comprising an effector molecule conjugated to the antibody. Embodiment 28. The isolated antibody of embodiment 27, wherein the effector molecule comprises a cytotoxic agent. Embodiment 29. The isolated antibody of embodiment 28, wherein the cytotoxic agent is selected from a DNA inhibitor, a topoisomerase inhibitor, or a tubulin inhibitor. Embodiment 30. The isolated antibody of embodiment 28 or embodiment 29, wherein the cytotoxic agent is selected from Monoimine indolinobenzodiazepene (DGN549C), Tesirine, Talirine, Duocarmycin (secoDUBA prodrug), NMS249 (anthracycline), PNU (anthracycline), Dxd (exatecan), Monomethyl auristatin F (MMAF), Monomethyl auristatin E (MMAE), Ravtansine (DM4), and Pyrrolobenzodiazepine (PBD). Embodiment 31. The isolated antibody of any one of embodiments 28-30, wherein the cytotoxic agent is DGN549C. Embodiment 32. The isolated antibody of embodiment 31, wherein the DGN549C is conjugated to the antibody at an S239C substitution of a IgG heavy chain constant region. Embodiment 33. A humanized or fully human version of the antibody of any one of the preceding embodiments. Embodiment 34. A conjugate comprising an anti-CD74 antibody and an effector molecule conjugated to the antibody, the anti-CD74 antibody comprising: i) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 2 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 2 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 3 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 3 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 4 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 4 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 5 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 5 with one or two amino acid substitutions;Attorney Docket No.01245-0062-00PCT and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 6 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 6 with one or two amino acid substitutions; or ii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 101 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 101 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 102 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 102 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 103 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 103 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 104 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 104 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 105 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 105 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 106 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 106 with one or two amino acid substitutions; or iii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 201 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 201 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 202 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 202 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 203 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 203 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 204 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 204 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 205 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 205 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 206 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 206 with one or two amino acid substitutions; iv) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 301 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 301 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 302 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 302Attorney Docket No.01245-0062-00PCT with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 303 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 303 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 304 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 304 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 305 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 305 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 306 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 306 with one or two amino acid substitutions; or v) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 501 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 501 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 502 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 502 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 503 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 503 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 504 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 504 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 505 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 505 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 506 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 506 with one or two amino acid substitutions; or vi) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 601 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 601 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 602 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 602 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 603 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 603 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 604 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 604 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 605 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 605 with oneAttorney Docket No.01245-0062-00PCT or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 606 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 606 with one or two amino acid substitutions; or vii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 701 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 701 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 702 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 702 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 703 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 703 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 704 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 704 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 705 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 705 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 706 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 706 with one or two amino acid substitutions; or viii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 801 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 801 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 802 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 802 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 803 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 803 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 804 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 804 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 805 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 805 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 806 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 806 with one or two amino acid substitutions; or ix) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 901 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 901 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 902 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 902Attorney Docket No.01245-0062-00PCT with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 903 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 903 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 904 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 904 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 905 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 905 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 906 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 906 with one or two amino acid substitutions; or x) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1001 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1001 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1002 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1002 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1003 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1003 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1004 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1004 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1005 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1005 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1006 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1006 with one or two amino acid substitutions; or xi) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1101 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1101 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1102 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1102 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1103 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1103 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1104 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1104 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1105 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1105 withAttorney Docket No.01245-0062-00PCT one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1106 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1106 with one or two amino acid substitutions; or xii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1201 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1201 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1202 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1202 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1203 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1203 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1204 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1204 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1205 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1205 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1206 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1206 with one or two amino acid substitutions; or xiii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1301 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1301 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1302 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1302 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1303 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1303 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1304 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1304 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1305 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1305 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1306 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1306 with one or two amino acid substitutions; or xiv) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1401 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1401 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1402 or HCDR2 comprising the amino acid sequence of SEQ IDAttorney Docket No.01245-0062-00PCT NO: 1402 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1403 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1403 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1404 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1404 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1405 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1405 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1406 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1406 with one or two amino acid substitutions; or xv) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1501 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1501 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1502 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1502 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1503 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1503 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1504 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1504 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1505 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1505 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1506 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1506 with one or two amino acid substitutions; or xvi) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1601 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1601 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1602 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1602 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1603 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1603 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1604 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1604 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1605 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1605Attorney Docket No.01245-0062-00PCT with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1606 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1606 with one or two amino acid substitutions; or xvii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1701 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1701 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1702 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1702 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1703 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1703 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1704 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1704 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1705 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1705 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1706 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1706 with one or two amino acid substitutions; or xviii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1801 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1801 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1802 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1802 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1803 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1803 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1804 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1804 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1805 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1805 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1806 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1806 with one or two amino acid substitutions; or xix) a VH that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 12 and a VL that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 18; orAttorney Docket No.01245-0062-00PCT xx) a VH that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 112 and a VL that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 118; or xxi) a VH that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 212 and a VL that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 218; or xxii) a VH that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 312 and a VL that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 318; or xxiii) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 512 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 518; or xxiv) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 612 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 618; or xxv) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 712 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 718; or xxvi) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 812 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 818; or xxvii) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 912 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 918; or xxviii) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1012 and a VL is atAttorney Docket No.01245-0062-00PCT least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1018; or xxix) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1112 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1118; or xxx) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1212 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1218; or xxxi) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1312 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1318; or xxxii) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1412 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1418; or xxxiii) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1512 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1518; or xxxiv) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1612 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1618; or xxxv) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1712 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1718; or xxxvi) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1812 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1818.Attorney Docket No.01245-0062-00PCT Embodiment 35. The conjugate of embodiment 34, wherein the effector molecule comprises a cytotoxic agent. Embodiment 36. The conjugate of embodiment 35, wherein the cytotoxic agent is selected from a DNA inhibitor, a topoisomerase inhibitor, or a tubulin inhibitor. Embodiment 37. The conjugate of embodiment 35 or embodiment 36, wherein the cytotoxic agent is selected from Monoimine indolinobenzodiazepene (DGN549C), Tesirine, Talirine, Duocarmycin (secoDUBA prodrug), NMS249 (anthracycline), PNU (anthracycline), Dxd (exatecan), Monomethyl auristatin F (MMAF), Monomethyl auristatin E (MMAE), Ravtansine (DM4), and Pyrrolobenzodiazepine (PBD). Embodiment 38. The conjugate of any one of embodiments 35-37, wherein the cytotoxic agent is DGN549C. Embodiment 39. The conjugate of any one of embodiments 34-38, wherein the anti-CD74 antibody comprises the isolated antibody of any one of claims 1, 3-12 and 16-26. Embodiment 40. A composition comprising the antibody of any one of embodiments 1-33 and a pharmaceutically acceptable carrier. Embodiment 41. A method of conditioning a subject to reduce an endogenous population of hematopoietic stem cells in the subject comprising administering an anti-CD74 antibody to the subject, the anti-CD74 antibody comprising the isolated antibody of any one of embodiments 1-13 and 16-26. Embodiment 42. The method of embodiment 41, further comprising an effector molecule conjugated to the antibody. Embodiment 43. The method of embodiment 42, wherein the effector molecule comprises a cytotoxic agent. Embodiment 44. The method of embodiment 43, wherein the cytotoxic agent is selected from a DNA inhibitor, a topoisomerase inhibitor, or a tubulin inhibitor. Embodiment 45. The method of embodiment 43 or embodiment 44, wherein the cytotoxic agent is selected from Monoimine indolinobenzodiazepene (DGN549C), Tesirine, Talirine, Duocarmycin (secoDUBA prodrug), NMS249 (anthracycline), PNU (anthracycline), Dxd (exatecan), Monomethyl auristatin F (MMAF), Monomethyl auristatin E (MMAE), Ravtansine (DM4), and Pyrrolobenzodiazepine (PBD). Embodiment 46. The method of any one of embodiments 43-45, wherein the cytotoxic agent is DGN549C. Embodiment 47. The method of any one of embodiments 41-46, wherein the anti-CD74 antibody is internalized by the endogenous population of hematopoietic stem cells.Attorney Docket No.01245-0062-00PCT Embodiment 48. The method of any one of embodiments 41-47, wherein the anti-CD74 antibody comprises an effector silencing modification. Embodiment 49. The method of any one of embodiments 41-48, wherein the hematopoietic stem cells are reduced in bone marrow. Embodiment 50. The method of any one of embodiments 41-49, wherein the hematopoietic stem cells are CD34+ cells. Embodiment 51. The method of any one of embodiments 41-50, wherein the hematopoietic stem cells are human cells. Embodiment 52. The method of any one of embodiments 41-51, comprising administering a composition comprising cells following the conditioning of the subject to reduce the endogenous population of hematopoietic stem cells. Embodiment 53. The method of any one of embodiments 41-52, comprising administering to the subject a composition comprising CD34+ human hematopoietic stem and / or progenitor cells (hHSPCs). Embodiment 54. The method of any one of embodiments 41-53, comprising administering a composition comprising CD34+ human hematopoietic stem and / or progenitor cells (hHSPCs) that comprise a genetic modification. Embodiment 55. The method of any one of embodiments 41-54, wherein the subject has a hemoglobinopathy. Examples of a hemoglobinopathy include, for example, sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). Embodiment 56. A nucleic acid encoding the antibody of any one of embodiments 1-26. Embodiment 57. A host cell comprising the nucleic acid of embodiment 56. Embodiment 58. A method of producing the antibody of any one of embodiments 1-26 comprising culturing the host cell of embodiment 57 under conditions wherein the antibody is expressed. Embodiment 59. The method of embodiment 58, further comprising purifying the antibody. BRIEF DESCRIPTION OF THE FIGURES

[0008] FIG.1 depicts an exemplary anti-CD74 antibody conjugated to an exemplary effector molecule.

[0009] FIGS.2A-2D show the binding of anti-CD74 antibodies from clone 1 (FIG.2A), clone 22 (FIG.2B), and clone 41 (FIG.2C) to primary human bone marrow CD34+ cells. FIG. 2D shows the antibody EC50 for each of the clones. Attorney Docket No.01245-0062-00PCT

[0010] FIGS.3A-3B show the binding of clone 3 anti-CD74 antibody to all CD34+CD90+ cells (FIG.3A), and FIG.3B shows the antibody EC50 comparison of clone 1 to clone 3.

[0011] FIGS.4A-4D show binding of anti-CD74 antibody and ADC equivalent binding to primary human bone marrow CD34+ cells for clones 1, 3, 22, and 41.

[0012] FIGS.5A-5C show the binding of anti-CD74 antibodies to primary cynomolgus monkey bone marrow CD34+ cells for each of clones 1, 22, and 41. FIG.5A shows the binding of anti-CD74 antibodies to primary cynomolgus monkey bone marrow CD34+ CD90+ cells. FIG.5B shows the binding of anti-CD74 antibodies to primary cynomolgus monkey bone marrow CD34+ CD90- cells. FIG.5C shows the binding of anti-CD74 antibodies to primary cynomolgus monkey bone marrow CD34+ cells.

[0013] FIGS.6A-6B show the internalization of anti-CD74 antibodies into primary human bone marrow CD34+ cells. FIG.6A shows the internalization of anti-CD74 antibodies into primary human bone marrow CD34+CD90+ cells. FIG.6B shows the internalization of anti- CD74 antibodies into primary human bone marrow CD34+CD90 - cells.

[0014] FIG.7 shows effector silencing of anti-CD74 antibodies.

[0015] FIGS.8A-8B show the cytotoxic effect of anti-CD74 ADCs on primary human bone marrow CD34+ cells. FIG.8A shows the cytotoxic effect of anti-CD74 ADCs on primary human bone marrow CD34+ cells by cell number. FIG.8B shows the cytotoxic effect of anti- CD74 ADCs on primary human bone marrow CD34+ cells by percent.

[0016] FIG.9 shows the cytotoxic effect of anti-CD74 ADCs on primary human bone marrow CD34+ cells for clone 3.

[0017] FIGS.10A-10B show the cytotoxic effect of anti-CD74 ADCs on primary cynomolgus monkey bone marrow CD34+ cells. FIG.10A shows the cytotoxic effect of anti- CD74 ADCs on primary cynomolgus monkey bone marrow CD34+ cells by cell number. FIG. 10B shows the cytotoxic effect of anti-CD74 ADCs on primary cynomolgus monkey bone marrow CD34+ cells by percent.

[0018] FIGS.11A-11B show the cytotoxic effect of anti-CD74 ADCs on a CD74 expressing cell line. FIG.11A shows the cytotoxic effect of anti-CD74 ADCs on a CD74 expressing cell line by cell number. FIG.11B shows the cytotoxic effect of anti-CD74 ADCs on a CD74 expressing cell line by percent.

[0019] FIG.12A-12B show the lack of cytotoxic effect of anti-CD74 ADCs on a CD74 knockout cell line. FIG.12A shows the cytotoxic effect of anti-CD74 ADCs on a CD74 knockout cell line by cell number. FIG.12B shows the cytotoxic effect of anti-CD74 ADCs on a CD74 knockout cell line by percent.Attorney Docket No.01245-0062-00PCT

[0020] FIG.13A-13C show evaluation of anti-CD74 antibody in Fc-dependent functional assays. FIG.13A shows ADCC. FIG.13B shows ADCP. FIG.13C shows CDC.

[0021] FIG.14A-14B show CD74 copy expression on cryopreserved human (FIG.14A) and NHP (FIG.14B) CD34+ bone marrow cell subsets.

[0022] FIG.15 shows CD74 expression on peripheral blood leukocyte subsets of human healthy donors, human subjects with SCD, and NHPs.

[0023] FIGS.16A-16B show bone marrow hematopoietic stem cell and progenitor cell depletion following a single IV administration of anti-CD74-DGN549c in humanized mice. FIG.16A shows administration of V-003-0105-001 and FIG.16B shows administration of anti- CD74 ADC.

[0024] FIGS.17A-17B show bone marrow hematopoietic stem cell and progenitor cell depletion following a single IV administration of anti-CD74-ADC in nonhuman primates at day 7 (FIG.17A) and day 21 (FIG.17B).

[0025] FIGS.18A-18B show kinetics of neutrophil (FIG.18A) and platelet (FIG, 18B) depletion following a single IV administration of anti-CD74-ADC in nonhuman primates.

[0026] FIGS.19A-19B show neutrophil (FIG.19A) and neutrophil (FIG.19B) engraftment following conditioning with a single IV administration of anti-CD74 ADC compared to a 4-day regimen of busulfan in nonhuman primates.

[0027] FIG.20 shows gene-edited chimerism following conditioning with a single IV administration of anti-CD74 ADC compared to a 4-day regimen of busulfan in nonhuman primates.

[0028] FIGS.21A-21B show plasma PK profiles of total ADC (FIG.21A) and total antibody (FIG.21B) in cynomolgus monkeys following single IV administration of anti-CD74 ADC.

[0029] FIG.22A-22B show individual plasma concentration-time profile of total antibody (FIG.22A) and total ADC (FIG.22B) following single IV administration of anti-CD74 ADC in cynomolgus monkeys.

[0030] FIG.23 shows individual plasma concentration-time profile of free payload FGN849 following single IV administration of anti-CD74 ADC in cynomolgus monkeys. DETAILED DESCRIPTION I. DEFINITIONS

[0031] In this application, the use of “or” means “and / or” unless stated otherwise. In the context of a multiple dependent claim, the use of “or” refers back to more than one precedingAttorney Docket No.01245-0062-00PCT independent or dependent claim in the alternative only. The terms “comprising,” “including,” and “having” can be used interchangeably herein.

[0032] The terms “CD74,” “DHLAG,” “CLIP,” “CD74 Antigen (Invariant Polypeptide Of Major Histocompatibility Complex, Class II Antigen-Associated),” “Poliovirus Receptor Related Immunoglobulin Domain Containing,”“CD74 Molecule, Major Histocompatibility Complex, Class II Invariant Chain,” “HLA Class II Histocompatibility Antigen Gamma Chain,” “Class II MHC-Associated Invariant Chain Peptide,” “HLA-DR Antigens-Associated Invariant Chain,” “Gamma Chain Of Class II Antigens,” “Ia-Associated Invariant Chain,” “MHC HLA- DR Gamma Chain,” “HLA-DR-Gamma,” “Ia Antigen-Associated Invariant Chain,” “CD74 Antigen,” “Ia-GAMMA,” “HLADG,” “P33,” “II,” and “Ii” are all used interchangeably and refer to a native, human CD74, unless otherwise specifically indicated (e.g. mouse CD74, cynomolgus CD74, etc.). The term includes full-length, unprocessed CD74 as well as any form of CD74 that results from processing in a cell. The term encompasses naturally occurring variants of human CD74, e.g., splice variants or allelic variants. External ID’s for CD74 gene include HGNC: 1697, NCBI Gene: 972, Ensembl: ENSG00000019582, OMIM: 142790, and UniProtKB: P04233.

[0033] “Affinity” refers to the strength of the sum total of noncovalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Unless indicated otherwise, as used herein, “binding affinity” refers to intrinsic binding affinity which reflects a 1:1 interaction between members of a binding pair (e.g., antibody and antigen). The affinity of a molecule X for its partner Y can generally be represented by the dissociation constant (KD). Affinity can be measured by common methods known in the art, including those described herein. Specific illustrative and exemplary embodiments for measuring binding affinity are described in the following.

[0034] An “affinity matured” antibody refers to an antibody with one or more alterations in one or more hypervariable regions (HVRs), compared to a parent antibody which does not possess such alterations, such alterations optionally resulting in an improvement in the affinity of the antibody for antigen.

[0035] The term “antibody” herein is used in the broadest sense and encompasses various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments so long as they exhibit the desired antigen-binding activity.

[0036] An “antibody fragment” refers to a molecule other than an intact antibody that comprises a portion of an intact antibody that binds the antigen to which the intact antibody binds. Examples of antibody fragments include but are not limited to Fv, Fab, Fab', Fab’-SH,Attorney Docket No.01245-0062-00PCT F(ab')2; diabodies; linear antibodies; single-chain antibody molecules (e.g. scFv); and multispecific antibodies formed from antibody fragments.

[0037] The term “block,” “crossblock,” or “cross-block,” in the context of an interaction between two or more molecules, is used herein to refer to inhibition or prevention of said interaction between the two or more molecules, wherein the inhibition or prevention of said interaction between the two or more molecules is complete or nearly complete under at least one condition. A “nearly complete” inhibition is a percent inhibition of about 70 - 99.9 %, and a “complete” inhibition is 100%. For example, a molecule is said to “block” an interaction between two or more other molecules if it completely or nearly completely inhibits such interaction at certain concentrations in a dose dependent manner.

[0038] The term “cancer” is used herein to refer to a group of cells that exhibit abnormally high levels of proliferation and growth. A cancer may be benign (also referred to as a benign tumor), pre-malignant, or malignant. Cancer cells may be solid cancer cells or leukemic cancer cells. The term “tumor” is used herein to refer to a cell or cells that comprise a cancer. The term “tumor growth” is used herein to refer to proliferation or growth by a cell or cells that comprise a cancer that leads to a corresponding increase in the size or extent of the cancer.

[0039] The term “chimeric” antibody refers to an antibody in which a portion of the heavy and / or light chain is derived from a particular source or species, while the remainder of the heavy and / or light chain is derived from a different source or species.

[0040] The “class” of an antibody refers to the type of constant domain or constant region possessed by its heavy chain. There are five major classes of antibodies: IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into subclasses (isotypes), e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. The heavy chain constant domains that correspond to the different classes of immunoglobulins are called ^, ^, ^, ^, and ^, respectively.

[0041] Administration “in combination with” one or more further therapeutic agents includes simultaneous (concurrent) and consecutive (sequential) administration in any order.

[0042] The term “conjugate,” “immunoconjugate,” or “antibody drug conjugate” as used herein refers to the linkage of an antibody or an antigen binding fragment thereof with another effector molecule, such as a cytotoxic agent, an immunotherapeutic agent, an imaging probe, and the like. The linkage can be covalent bonds, or non-covalent interactions such as through electrostatic forces. Various linkers, known in the art, can be employed in order to form the conjugate. Additionally, the conjugate can be provided in the form of a fusion protein that may be expressed from a polynucleotide encoding the conjugate. As used herein, “fusion protein” refers to proteins created through the joining of two or more genes or gene fragments whichAttorney Docket No.01245-0062-00PCT originally coded for separate proteins (including peptides and polypeptides). Translation of the fusion gene results in a single protein with functional properties derived from each of the original proteins.

[0043] The term “cytotoxic agent” as used herein refers to a substance that inhibits or prevents a cellular function and / or causes cell death or destruction. Cytotoxic agents include, but are not limited to, radioactive isotopes (e.g., At211, I131, I125, Y90, Re186, Re188, Sm153, Bi212, P32, Pb212and radioactive isotopes of Lu); chemotherapeutic agents or drugs (e.g., methotrexate, adriamicin, vinca alkaloids (vincristine, vinblastine, etoposide), doxorubicin, melphalan, mitomycin C, chlorambucil, daunorubicin or other intercalating agents); growth inhibitory agents; enzymes and fragments thereof such as nucleolytic enzymes; antibiotics; toxins such as small molecule toxins (e.g., DNA inhibitors, topoisomerase inhibitors, or a tubulin inhibitors) or enzymatically active toxins of bacterial, fungal, plant or animal origin, including fragments and / or variants thereof.

[0044] “Effector functions” refer to those biological activities attributable to the Fc region of an antibody, which vary with the antibody isotype. Examples of antibody effector functions include: C1q binding and complement dependent cytotoxicity (CDC); Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; down regulation of cell surface receptors (e.g. B cell receptor); and B cell activation.

[0045] An “effective amount” of an agent, e.g., a pharmaceutical formulation, refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic or prophylactic result.

[0046] The term “Fc region” herein is used to define a C-terminal region of an immunoglobulin heavy chain that contains at least a portion of the constant region. The term includes native sequence Fc regions and variant Fc regions. In some embodiments, a human IgG heavy chain Fc region extends from Cys226, or from Pro230, to the carboxyl-terminus of the heavy chain. However, the C-terminal lysine (Lys447) of the Fc region may or may not be present (numbering in this paragraph is according to the EU numbering system, also called the EU index, as described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD, 1991).

[0047] “Framework,” “framework region,” or “FR” refers to variable domain residues other than hypervariable region (HVR) residues. The FR of a variable domain generally consists of four FR domains: FR1, FR2, FR3, and FR4. Accordingly, the HVR and FR sequences generally appear in the following sequence in VH (or VL): FR1-H1(L1)-FR2-H2(L2)-FR3- H3(L3)-FR4.Attorney Docket No.01245-0062-00PCT

[0048] The terms “full length antibody,” “intact antibody,” and “whole antibody” are used herein interchangeably to refer to an antibody having a structure substantially similar to a native antibody structure or having heavy chains that contain an Fc region as defined herein.

[0049] The terms “host cell,” “host cell line,” and “host cell culture” are used interchangeably and refer to cells into which exogenous nucleic acid has been introduced, including the progeny of such cells. Host cells include “transformants” and “transformed cells,” which include the primary transformed cell and progeny derived therefrom without regard to the number of passages. Progeny may not be completely identical in nucleic acid content to a parent cell and may contain mutations. Mutant progeny that have the same function or biological activity as screened or selected for in the originally transformed cell are included herein.

[0050] A “human antibody” is one which possesses an amino acid sequence which corresponds to that of an antibody produced by a human or a human cell or derived from a non- human source that utilizes human antibody repertoires or other human antibody-encoding sequences. This definition of a human antibody specifically excludes a humanized antibody comprising non-human antigen-binding residues.

[0051] As used herein, the term "humanized" refers to an antibody in which some, most or all of the amino acids outside the CDR domains of a non-human antibody are replaced with corresponding amino acids derived from human immunoglobulins. In some embodiments of a humanized form of an antibody, some, most or all of the amino acids outside the CDR domains have been replaced with amino acids from human immunoglobulins, whereas some, most or all amino acids within one or more CDR regions are unchanged. Small additions, deletions, insertions, substitutions or modifications of amino acids are permissible as long as they do not abrogate the ability of the antibody to bind to a particular antigen. A "humanized" antibody retains an antigenic specificity similar to that of the original antibody.

[0052] The term “variable region” or “variable domain” refers to the domain of an antibody heavy or light chain that is involved in binding the antibody to antigen. The variable domains of the heavy chain and light chain (VH and VL, respectively) of a native antibody generally have similar structures, with each domain comprising four conserved framework regions (FRs) and three hypervariable regions (HVRs). (See, e.g., Kindt et al. Kuby Immunology, 6thed., W.H. Freeman and Co., page 91 (2007).) A single VH or VL domain may be sufficient to confer antigen-binding specificity. Furthermore, antibodies that bind a particular antigen may be isolated using a VH or VL domain from an antibody that binds the antigen to screen a library of complementary VL or VH domains, respectively. See, e.g., Portolano et al., J. Immunol.150:880-887 (1993); Clarkson et al., Nature 352:624-628 (1991).Attorney Docket No.01245-0062-00PCT

[0053] A “human consensus framework” is a framework which represents the most commonly occurring amino acid residues in a selection of human immunoglobulin VL or VH framework sequences. Generally, the selection of human immunoglobulin VL or VH sequences is from a subgroup of variable domain sequences. Generally, the subgroup of sequences is a subgroup as in Kabat et al., Sequences of Proteins of Immunological Interest, Fifth Edition, NIH Publication 91-3242, Bethesda MD (1991), vols.1-3. In some embodiments, for the VL, the subgroup is subgroup kappa I as in Kabat et al., supra. In some embodiments, for the VH, the subgroup is subgroup III as in Kabat et al., supra.

[0054] The term “hypervariable region” or “HVR” as used herein refers to each of the regions of an antibody variable domain which are hypervariable in sequence (“complementarity determining regions” or “CDRs”) and / or form structurally defined loops (“hypervariable loops”) and / or contain the antigen-contacting residues (“antigen contacts”). Generally, antibodies comprise six HVRs: three in the VH (H1, H2, H3), and three in the VL (L1, L2, L3). The CDRs are the target protein-binding site of the antibody chains that harbors specificity for such target protein. There are three CDRs (CDR1-3, numbered sequentially from the N-terminus) in each human VL or VH, constituting about 15-20% of the variable domains. CDRs can be referred to by their region and order. For example, “VHCDR1” or “HCDR1” both refer to the first CDR of the heavy chain variable region. The CDRs are structurally complementary to the epitope of the target protein and are thus directly responsible for the binding specificity. The remaining stretches of the VL or VH, the so-called framework regions, exhibit less variation in amino acid sequence (Kuby, Immunology, 4th ed., Chapter 4. W.H. Freeman & Co., New York, 2000). The amino acid sequence boundaries of a given CDR can be determined using any of a number of well-known schemes, including those described by Kabat et al. (1991), “Sequences of Proteins of Immunological Interest,” 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (“Kabat” numbering scheme), Al-Lazikani et al., (1997) JMB 273, 927-948 (“Chothia” numbering scheme) and ImMunoGenTics (IMGT) numbering (Lefranc, M.-P., The Immunologist, 7, 132-136 (1999); Lefranc, M.-P. et al., Dev. Comp. Immunol., 27, 55-77 (2003) (“IMGT” numbering scheme).

[0055] An “immunoconjugate” is an antibody conjugated to one or more heterologous molecule(s), including but not limited to an effector molecule, such as a cytotoxic agent.

[0056] An “individual” or “subject” is a mammal. Mammals include, but are not limited to, domesticated animals (e.g., cows, sheep, cats, dogs, and horses), primates (e.g., humans and non-human primates such as monkeys), rabbits, and rodents (e.g., mice and rats). In certain embodiments, the individual or subject is a human.Attorney Docket No.01245-0062-00PCT

[0057] An “isolated” antibody is one which has been separated from a component of its natural environment. In some embodiments, an antibody is purified to greater than 95% or 99% purity as determined by, for example, electrophoretic (e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatographic (e.g., ion exchange or reverse phase HPLC). For review of methods for assessment of antibody purity, see, e.g., Flatman et al., J. Chromatogr. B 848:79-87 (2007).

[0058] The term “monoclonal antibody” as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical and / or bind the same epitope, except for possible variant antibodies, e.g., containing naturally occurring mutations or arising during production of a monoclonal antibody preparation, such variants generally being present in minor amounts. In contrast to polyclonal antibody preparations, which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody of a monoclonal antibody preparation is directed against a single determinant on an antigen. Thus, the modifier “monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies and is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies to be used in accordance with the present disclosure may be made by a variety of techniques, including but not limited to the hybridoma method, recombinant DNA methods, phage-display methods, and methods utilizing transgenic animals containing all or part of the human immunoglobulin loci, such methods and other exemplary methods for making monoclonal antibodies being described herein.

[0059] A “naked antibody” refers to an antibody that is not conjugated to a heterologous moiety (e.g., a cytotoxic moiety) or radiolabel. The naked antibody may be present in a pharmaceutical formulation.

[0060] “Native antibodies” refer to naturally occurring immunoglobulin molecules with varying structures. For example, native IgG antibodies are heterotetrameric glycoproteins of about 150,000 daltons, composed of two identical light chains and two identical heavy chains that are disulfide-bonded. From N- to C-terminus, each heavy chain has a variable region (VH), also called a variable heavy domain or a heavy chain variable domain, followed by three constant domains (CH1, CH2, and CH3). Similarly, from N- to C-terminus, each light chain has a variable region (VL), also called a variable light domain or a light chain variable domain, followed by a constant light (CL) domain. The light chain of an antibody may be assigned to one of two types, called kappa (κ) and lambda (λ), based on the amino acid sequence of its constant domain.Attorney Docket No.01245-0062-00PCT

[0061] “Percent (%) amino acid sequence identity” with respect to a reference polypeptide sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the reference polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. For purposes herein, however, % amino acid sequence identity values are generated using the sequence comparison computer program ALIGN-2. The ALIGN-2 sequence comparison computer program was authored by Genentech, Inc., and the source code has been filed with user documentation in the U.S. Copyright Office, Washington D.C., 20559, where it is registered under U.S. Copyright Registration No. TXU510087. The ALIGN-2 program is publicly available from Genentech, Inc., South San Francisco, California, or may be compiled from the source code. The ALIGN-2 program should be compiled for use on a UNIX operating system, including digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary.

[0062] In situations where ALIGN-2 is employed for amino acid sequence comparisons, the % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B (which can alternatively be phrased as a given amino acid sequence A that has or comprises a certain % amino acid sequence identity to, with, or against a given amino acid sequence B) is calculated as follows: 100 times the fraction X / Y where X is the number of amino acid residues scored as identical matches by the sequence alignment program ALIGN-2 in that program’s alignment of A and B, and where Y is the total number of amino acid residues in B. It will be appreciated that where the length of amino acid sequence A is not equal to the length of amino acid sequence B, the % amino acid sequence identity of A to B will not equal the % amino acid sequence identity of B to A. Unless specifically stated otherwise, all % amino acid sequence identity values used herein are obtained as described in the immediately preceding paragraph using the ALIGN-2 computer program.Attorney Docket No.01245-0062-00PCT

[0063] The term “pharmaceutical formulation” or “pharmaceutical composition” refers to a preparation which is in such form as to permit the biological activity of an active ingredient contained therein to be effective, and which contains no additional components which are unacceptably toxic to a subject to which the formulation would be administered.

[0064] A “pharmaceutically acceptable carrier” refers to an ingredient in a pharmaceutical formulation or composition, other than an active ingredient, which is nontoxic to a subject. A pharmaceutically acceptable carrier includes, but is not limited to, a buffer, excipient, stabilizer, or preservative.

[0065] As used herein, “treatment” (and grammatical variations thereof such as “treat” or “treating”) refers to clinical intervention in an attempt to alter the natural course of the individual being treated and can be performed either for prophylaxis or during the course of clinical pathology. Desirable effects of treatment include, but are not limited to, preventing occurrence or recurrence of disease, alleviation of symptoms, diminishment of any direct or indirect pathological consequences of the disease, preventing metastasis, decreasing the rate of disease progression, amelioration or palliation of the disease state, and remission or improved prognosis. In some embodiments, antibodies of the disclosure are used to delay development of a disease or to slow the progression of a disease.

[0066] The term “vector,” as used herein, refers to a nucleic acid molecule capable of propagating another nucleic acid to which it is linked. The term includes the vector as a self- replicating nucleic acid structure as well as the vector incorporated into the genome of a host cell into which it has been introduced. Certain vectors are capable of directing the expression of nucleic acids to which they are operatively linked. Such vectors are referred to herein as “expression vectors.” II. COMPOSITIONS AND METHODS

[0067] Anti-CD74 antibodies, anti-CD74 antibody conjugates, compositions comprising the described antibodies, and methods of their use are provided. A. Exemplary Anti-CD74 Antibodies

[0068] The Sequence Table below provides the sequences of certain embodiments of the antibodies disclosed and claimed herein.

[0069] In some embodiments, antibodies are provided that bind to CD74.

[0070] In some embodiments, the antibodies bind to human CD74. In some embodiments, the antibodies bind to human and / or cynomolgus CD74.

[0071] In certain embodiments, an anti-CD74 antibody comprises a heavy chain variable region (“VH”) comprising VH CDR1, CDR2 and / or CDR3 of any of the anti-CD74 antibodiesAttorney Docket No.01245-0062-00PCT provided herein (i.e., antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56).

[0072] In certain embodiments, an anti-CD74 antibody comprises a VH comprising VH CDR1, CDR2 and / or CDR3 of any of the anti-CD74 antibodies provided herein and a VL comprising CDR1, CDR2 and / or CDR3 of any of the CD74 antibodies provided herein. In certain embodiments, an anti-CD74 antibody comprises a VH comprising VH CDR1, CDR2 and / or CDR3 of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56, and a VL comprising VL CDR1, CDR2, and / or CDR3 of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56, optionally wherein the VH and VL CDRs are from the same antibody clone.

[0073] In some embodiments, antibodies comprising the following are provided: (a) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 2 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 2 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 3 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 3 with one or two amino acid substitutions; with or without (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 4 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 4 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 5 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 5 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 6 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 6 with one or two amino acid substitutions; or (b) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 101 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 101 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 102 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 102 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 103 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 103 with one or two amino acid substitutions; with or without (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 104 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 104 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 105 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 105 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 106 orAttorney Docket No.01245-0062-00PCT LCDR3 comprising the amino acid sequence of SEQ ID NO: 106 with one or two amino acid substitutions; or (c) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 201 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 201 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 202 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 202 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 203 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 203 with one or two amino acid substitutions; with or without (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 204 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 204 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 205 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 205 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 206 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 206 with one or two amino acid substitutions; or (d) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 301 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 301 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 302 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 302 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 303 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 303 with one or two amino acid substitutions; with or without (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 304 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 304 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 305 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 305 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 306 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 306 with one or two amino acid substitutions; or (e) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 501 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 501 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 502 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 502 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 503 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 503 with one or two amino acid substitutions; with or without (d) LCDR1 comprising the amino acid sequence of SEQ ID NO:Attorney Docket No.01245-0062-00PCT 504 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 504 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 505 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 505 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 506 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 506 with one or two amino acid substitutions; or (f) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 601 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 601 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 602 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 602 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 603 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 603 with one or two amino acid substitutions; with or without (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 604 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 604 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 605 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 605 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 606 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 606 with one or two amino acid substitutions; or (g) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 701 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 701 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 702 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 702 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 703 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 703 with one or two amino acid substitutions; with or without (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 704 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 704 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 705 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 705 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 706 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 706 with one or two amino acid substitutions; or (h) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 801 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 801 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 802 or HCDR2Attorney Docket No.01245-0062-00PCT comprising the amino acid sequence of SEQ ID NO: 802 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 803 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 803 with one or two amino acid substitutions; with or without (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 804 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 804 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 805 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 805 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 806 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 806 with one or two amino acid substitutions; or (i) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 901 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 901 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 902 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 902 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 903 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 903 with one or two amino acid substitutions; with or without (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 904 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 904 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 905 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 905 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 906 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 906 with one or two amino acid substitutions; or (j) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1001 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1001 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1002 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1002 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1003 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1003 with one or two amino acid substitutions; with or without (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1004 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1004 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1005 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1005 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1006 orAttorney Docket No.01245-0062-00PCT LCDR3 comprising the amino acid sequence of SEQ ID NO: 1006 with one or two amino acid substitutions; or (k) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1101 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1101 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1102 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1102 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1103 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1103 with one or two amino acid substitutions; with or without (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1104 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1104 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1105 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1105 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1106 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1106 with one or two amino acid substitutions; or (l) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1201 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1201 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1202 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1202 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1203 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1203 with one or two amino acid substitutions; with or without (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1204 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1204 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1205 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1205 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1206 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1206 with one or two amino acid substitutions; or (m) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1301 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1301 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1302 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1302 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1303 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1303 with one or two amino acid substitutions; with or without (d) LCDR1 comprising the amino acid sequence of SEQ ID NO:Attorney Docket No.01245-0062-00PCT 1304 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1304 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1305 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1305 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1306 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1306 with one or two amino acid substitutions; or (n) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1401 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1401 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1402 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1402 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1403 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1403 with one or two amino acid substitutions; with or without (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1404 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1404 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1405 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1405 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1406 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1406 with one or two amino acid substitutions; or (o) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1501 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1501 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1502 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1502 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1503 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1503 with one or two amino acid substitutions; with or without (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1504 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1504 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1505 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1505 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1506 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1506 with one or two amino acid substitutions; or (p) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1601 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1601 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1602 or HCDR2Attorney Docket No.01245-0062-00PCT comprising the amino acid sequence of SEQ ID NO: 1602 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1603 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1603 with one or two amino acid substitutions; with or without (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1604 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1604 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1605 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1605 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1606 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1606 with one or two amino acid substitutions; or (q) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1701 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1701 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1702 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1702 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1703 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1703 with one or two amino acid substitutions; with or without (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1704 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1704 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1705 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1705 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1706 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1706 with one or two amino acid substitutions; or (r) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1801 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1801 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1802 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1802 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1803 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1803 with one or two amino acid substitutions; with or without (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1804 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1804 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1805 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1805 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1806 orAttorney Docket No.01245-0062-00PCT LCDR3 comprising the amino acid sequence of SEQ ID NO: 1806 with one or two amino acid substitutions.

[0074] In some embodiments, the one or two amino acid substitutions are conservative amino acid substitutions. In some embodiments, the one or two amino acid substitutions are non- conservative amino acid substitutions.

[0075] In some embodiments, antibodies comprising the following are provided: (a) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 2; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 3; with or without (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 4; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 5; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 6; or (b) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 101; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 102; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 103; with or without (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 104; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 105; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 106; or (c) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 201; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 202; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 203; with or without (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 204; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 205; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 206; or (d) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 301; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 302; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 303; with or without (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 304; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 305; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 306; or (e) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 501; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 502; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 503; with or without (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 504; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 505; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO:; or (f) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 601; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 602; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO:603; with or without (d) LCDR1 comprising the amino acid sequenceAttorney Docket No.01245-0062-00PCT of SEQ ID NO: 604; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 605; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 606; or (g) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 701; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 702; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 703; with or without (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 704; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 705; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 706; or (h) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO:; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 802; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 803; with or without (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 804; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 805; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 806; or (i) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 901; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 902; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 903; with or without (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 904; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 905; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 906; or (j) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1001; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1002; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1003; with or without (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1004; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1005; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1006; or (k) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO:; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1102; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1103; with or without (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1104; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1105; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1106; or (l) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1201; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1202; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1203; with or without (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1204; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1205; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1206; or (m) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1301; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1302; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1303; with or without (d) LCDR1 comprising the amino acidAttorney Docket No.01245-0062-00PCT sequence of SEQ ID NO: 1304; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1305; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1306; or (n) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1401; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1402; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1403; with or without (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1404; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1405; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1406; or (o) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1501; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1502; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1503; with or without (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1504; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1505; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO:1506; or (p) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1601; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1602; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1603; with or without (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1604; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1605; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1606; or (q) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1701 (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1702; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1703; with or without (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1704; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1705; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1706; or (r) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1801; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1802; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1803; with or without (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1804; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1805; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1806.

[0076] In certain embodiments, an anti-CD74 antibody comprises a VL comprising VL CDR1, CDR2 and CDR3 of any of the anti-CD74 antibodies provided herein. In certain embodiments, an anti-CD74 antibody comprises a VL comprising VL CDR1, CDR2 and CDR3 of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56.

[0077] In some embodiments, an anti-CD74 antibody may comprise:Attorney Docket No.01245-0062-00PCT (a) a VH comprising the amino acid sequence of the VH CDR1, CDR2 and CDR3 of antibody clone number 22 and a VL comprising the VL CDR1, CDR2 and CDR3 of antibody clone number 22; or (b) a VH comprising the amino acid sequence of the VH CDR1, CDR2 and CDR3 of antibody clone number 3 and a VL comprising the VL CDR1, CDR2 and CDR3 of antibody clone number 3; or (c) a VH comprising the amino acid sequence of the VH CDR1, CDR2 and CDR3 of antibody clone number 1 and a VL comprising the VL CDR1, CDR2 and CDR3 of antibody clone number 1; or (d) a VH comprising the amino acid sequence of the VH CDR1, CDR2 and CDR3 of antibody clone number 41 and a VL comprising the VL CDR1, CDR2 and CDR3 of antibody clone number 41; or (e) a VH comprising the amino acid sequence of the VH CDR1, CDR2 and CDR3 of antibody clone number 93 and a VL comprising the VL CDR1, CDR2 and CDR3 of antibody clone number 93; or (f) a VH comprising the amino acid sequence of the VH CDR1, CDR2 and CDR3 of antibody clone number 95 and a VL comprising the VL CDR1, CDR2 and CDR3 of antibody clone number 95; or (g) a VH comprising the amino acid sequence of the VH CDR1, CDR2 and CDR3 of antibody clone number 41 and a VL comprising the VL CDR1, CDR2 and CDR3 of antibody clone number 4; or (h) a VH comprising the amino acid sequence of the VH CDR1, CDR2 and CDR3 of antibody clone number 7 and a VL comprising the VL CDR1, CDR2 and CDR3 of antibody clone number 7; or (i) a VH comprising the amino acid sequence of the VH CDR1, CDR2 and CDR3 of antibody clone number 53 and a VL comprising the VL CDR1, CDR2 and CDR3 of antibody clone number 53; or (j) a VH comprising the amino acid sequence of the VH CDR1, CDR2 and CDR3 of antibody clone number 66 and a VL comprising the VL CDR1, CDR2 and CDR3 of antibody clone number 66; or (k) a VH comprising the amino acid sequence of the VH CDR1, CDR2 and CDR3 of antibody clone number 68 and a VL comprising the VL CDR1, CDR2 and CDR3 of antibody clone number 68; orAttorney Docket No.01245-0062-00PCT (l) a VH comprising the amino acid sequence of the VH CDR1, CDR2 and CDR3 of antibody clone number 76 and a VL comprising the VL CDR1, CDR2 and CDR3 of antibody clone number 76; or (m) a VH comprising the amino acid sequence of the VH CDR1, CDR2 and CDR3 of antibody clone number 77 and a VL comprising the VL CDR1, CDR2 and CDR3 of antibody clone number 77; or (n) a VH comprising the amino acid sequence of the VH CDR1, CDR2 and CDR3 of antibody clone number 60 and a VL comprising the VL CDR1, CDR2 and CDR3 of antibody clone number 60; or (o) a VH comprising the amino acid sequence of the VH CDR1, CDR2 and CDR3 of antibody clone number 61 and a VL comprising the VL CDR1, CDR2 and CDR3 of antibody clone number 61; or (p) a VH comprising the amino acid sequence of the VH CDR1, CDR2 and CDR3 of antibody clone number 33 and a VL comprising the VL CDR1, CDR2 and CDR3 of antibody clone number 33; or (q) a VH comprising the amino acid sequence of the VH CDR1, CDR2 and CDR3 of antibody clone number 49 and a VL comprising the VL CDR1, CDR2 and CDR3 of antibody clone number 49; or (r) a VH comprising the amino acid sequence of the VH CDR1, CDR2 and CDR3 of antibody clone number 56 and a VL comprising the VL CDR1, CDR2 and CDR3 of antibody clone number 56.

[0078] The Sequence Table below provides the heavy and light chain variable region sequences of certain disclosed antibodies.

[0079] In certain embodiments, an anti-CD74 antibody comprises a VH comprising the amino acid sequence of the VH of any of the CD74 antibodies provided herein. In certain embodiments, an anti-CD74 antibody comprises a VH comprising the amino acid sequence of the VH of any one of the antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56.

[0080] In some embodiments, an anti-CD74 antibody comprises the VH of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56 but with 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, deletions, and / or insertions. In some embodiments, an anti-CD74 antibody comprises the VH of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56 but with 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 reversion substitutions.Attorney Docket No.01245-0062-00PCT

[0081] In some embodiments, an anti-CD74 antibody comprises the VH of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56 but with 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions outside the complementarity determining regions (CDRs), such as 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 conservative substitutions outside the CDRs. In some embodiments, an anti-CD74 antibody comprises the VH of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56 but with 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 reversion substitutions outside the complementarity determining regions (CDRs).

[0082] In some embodiments, an anti-CD74 antibody comprises the VH of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56 but with 1, 2, 3, 4, or 5 amino acid substitutions in the framework regions of the VH sequence, such as 1, 2, 3, 4, or 5 conservative substitutions. In some embodiments, an anti-CD74 antibody comprises the VH of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56 but with 1, 2, 3, 4, or 5 reversion substitutions in the framework regions of the VH sequence.

[0083] In some embodiments, an anti-CD74 antibody comprises the VH and VL CDRs of any of the anti-CD74 antibodies described herein, wherein each CDR comprises 0, 1, 2 or 3 amino acid additions, substitutions (e.g., conservative substitutions), or deletions.

[0084] In certain embodiments, an anti-CD74 antibody comprises a VH that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the VH of any of the anti-CD74 antibodies provided herein. In certain embodiments, a CD74 antibody comprises a VL comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of the VL of any one of the anti-CD74 antibodies provided herein.

[0085] In some embodiments, an isolated antibody that binds human CD74 is provided, wherein the antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein: a) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 12 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 18; or b) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 112 and the VL is at least 90%,Attorney Docket No.01245-0062-00PCT 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 118; or c) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 212 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 218; or d) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 312 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 318; or e) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 512 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 518; or f) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 612 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 618; or g) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 712 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 718; or h) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 812 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 818; or i) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 912 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 918; or j) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1012 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1018; orAttorney Docket No.01245-0062-00PCT k) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1112 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1118; or l) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1212 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1218; or m) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1312 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1318; or n) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1412 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1418; or o) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1512 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1518; or p) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1612 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1618; or q) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1712 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1718; or r) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1812 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1818.

[0086] In some embodiments, the isolated antibody comprises: a) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 12 and a VL is at least 90%, 91%, 92%,Attorney Docket No.01245-0062-00PCT 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 18; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 2; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 3; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 4; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 5; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 6; or b) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 112 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 118; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 101; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 102; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 103; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 104; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 105; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 106; or c) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 212 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 218; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 201; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 202; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 203; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 204; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 205; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 206; or d) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 312 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 318; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 301; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 302; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 303; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 304; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 305; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 306; or e) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 512 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 518; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 501; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 502; (c) HCDR3 comprising theAttorney Docket No.01245-0062-00PCT amino acid sequence of SEQ ID NO: 503; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 504; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 505; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 506; or f) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 612 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 618; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 601; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 602; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 603; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 604; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 605; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 606; or g) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 712 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 718; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 701; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 702; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 703; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 704; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 705; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 706; or h) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 812 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 818; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 801; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 802; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 803; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 804; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 805; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 806; or i) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 912 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 918; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 901; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 902; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 903; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 904; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 905; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 906; orAttorney Docket No.01245-0062-00PCT j) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1012 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1018; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1001; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1002; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1003; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1004; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1005; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1006; or k) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1112 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1118; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1101; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1102; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1103; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1104; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1105; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1106; or l) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1212 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1218; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1201; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1202; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1203; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1204; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1205; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1206; or m) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1312 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1318; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1301; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1302; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1303; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1304; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1305; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1306; or n) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1412 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQAttorney Docket No.01245-0062-00PCT ID NO: 1418; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1401; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1402; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1403; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1404; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1405; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1406; or o) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1512 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1518; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1501; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1502; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1503; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1504; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1505; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1506; or p) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1612 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1618; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1601; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1602; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1603; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1604; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1605; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1606; or q) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1712 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1718; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1701; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1702; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1703; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1704; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1705; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1706; or r) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1812 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1818; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1801; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1802; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1803; (d) LCDR1 comprising the amino acid sequence ofAttorney Docket No.01245-0062-00PCT SEQ ID NO: 1804; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1805; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1806.

[0087] In certain embodiments, an anti-CD74 antibody comprises a VH CDR1, CDR2, and CDR3 comprising the amino acid sequences of the VH CDRs of any of the anti-CD74 antibodies provided herein and comprises a VH that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the VH of any of the anti-CD74 antibodies provided herein. In certain embodiments, a CD74 antibody comprises a VH comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of the VH of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56. In certain embodiments, the VH of the antibody differs from that of the VH sequences shown in the Sequence Table due to 1, 2, 3, 4, or 5 amino acid substitutions in the framework regions of the VH sequence, such as 1, 2, 3, 4, or 5 conservative substitutions. In certain embodiments, the VH of the antibody differs from that of the VH sequences shown in the Sequence Table due to 1, 2, 3, 4, or 5 reversion substitutions in the framework regions of the VH sequence.

[0088] In certain embodiments, an anti-CD74 antibody comprises a VH consisting of the amino acid sequence of the VH of any of the anti-CD74 antibodies provided herein. In certain embodiments, an anti-CD74 antibody comprises a VH that consists of the amino acid sequence of the VH of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56.

[0089] In certain embodiments, an anti-CD74 antibody comprises a VL comprising the amino acid sequence of the VL of any of the anti-CD74 antibodies provided herein. In certain embodiments, an anti-CD74 antibody comprises a VL comprising the amino acid sequence of the VL of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56.

[0090] In certain embodiments, an anti-CD74 antibody comprises a VH that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical the amino acid sequence of the VH of any of the anti-CD74 antibodies provided herein and a VL that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of the VL of the corresponding anti-CD74 antibody. In certain embodiments, an anti-CD74 antibody comprises a VH that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of the VH of any one ofAttorney Docket No.01245-0062-00PCT antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56 and a VL that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of the VL of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56, respectively (i.e., the VH and VL of clone 22, the VH and VL of clone 3, the VH and VL of clone 1, the VH and VL of clone 41, the VH and VL of clone 93, the VH and VL of clone 95, the VH and VL of clone 4, the VH and VL of clone 7, the VH and VL of clone 53, the VH and VL of clone 66, the VH and VL of clone 68, the VH and VL of clone 76, the VH and VL of clone 77, the VH and VL of clone 60, the VH and VL of clone 61, the VH and VL of clone 33, the VH and VL of clone 49, the VH and VL of clone 56).

[0091] In certain embodiments, an anti-CD74 antibody comprises a VH consisting of the amino acid sequence of the VH of any of the anti-CD74 antibodies provided herein and a VL comprising the amino acid sequence of the VL of the corresponding anti-CD74 antibody. In certain embodiments, an anti-CD74 antibody comprises a VH that consists of the amino acid sequence of the VH of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56 and a VL that consists of the amino acid sequence of the VL of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56, respectively (i.e., the VH and VL of clone 22, the VH and VL of clone 3, the VH and VL of clone 1, the VH and VL of clone 41, the VH and VL of clone 93, the VH and VL of clone 95, the VH and VL of clone 4, the VH and VL of clone 7, the VH and VL of clone 53, the VH and VL of clone 66, the VH and VL of clone 68, the VH and VL of clone 76, the VH and VL of clone 77, the VH and VL of clone 60, the VH and VL of clone 61, the VH and VL of clone 33, the VH and VL of clone 49, the VH and VL of clone 56).

[0092] In some embodiments, an anti-CD74 antibody comprises the VL of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56 but with 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, deletions, and / or insertions. In some embodiments, an anti-CD74 antibody comprises the VL of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56 but with 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 reversion substitutions.

[0093] In some embodiments, an anti-CD74 antibody comprises the VL of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56 but with 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions outside the complementarity determining regions (CDRs), such as 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 conservative substitutions outside the CDRs. In some embodiments, an anti-CD74 antibody comprises the VL of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56 butAttorney Docket No.01245-0062-00PCT with 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 reversion substitutions outside the complementarity determining regions (CDRs).

[0094] In certain embodiments, an anti-CD74 antibody comprises a VL CDR1, CDR2, and CDR3 comprising the amino acid sequences of the VL CDRs of any of the anti-CD74 antibodies provided herein and comprises a VL that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the VL of any of the anti-CD74 antibodies provided herein. In certain embodiments, an anti-CD74 antibody comprises a VL comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of the VL of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56. In certain embodiments, the VL of the antibody differs from that of the VL sequences shown in the Sequence Table due to 1, 2, 3, 4, or 5 amino acid substitutions in the framework regions of the VL sequence, such as 1, 2, 3, 4, or 5 conservative substitutions. In certain embodiments, the VL of the antibody differs from that of the VL sequences shown in the Sequence Table due to 1, 2, 3, 4, or 5 reversion substitutions.

[0095] In certain embodiments, an anti-CD74 antibody comprises a VL consisting of the amino acid sequence of the VL of any of the anti-CD74 antibodies provided herein. In certain embodiments, an anti-CD74 antibody comprises a VL that consists of the amino acid sequence of the VL of any one of antibody clone numbers 22, 3, 1,41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56.

[0096] In certain embodiments, an anti-CD74 antibody comprises a VH comprising the amino acid sequence of the VH of any of the anti-CD74 antibodies provided herein and comprises a VL comprising the amino acid sequence of the VL of any of the same anti-CD74 antibodies provided herein. In certain of these embodiments, an anti-CD74 antibody comprises a VH comprising the amino acid sequence of the VH of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56 and a VL comprising the amino acid sequence of the VL of any one of antibody clone numbers 22, 3, 1, or 41, optionally wherein the VH and VL are from the same antibody clone number.

[0097] In certain embodiments, the VH of the antibody is that of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56, but with 1, 2, 3, 4, or 5 amino acid substitutions in the framework regions of the VH sequence, such as 1, 2, 3, 4, or 5 conservative substitutions, and the VL is that of any one of the same antibody from the list above. In certain embodiments, however, the VH of the antibody is that of any one of antibodyAttorney Docket No.01245-0062-00PCT clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56, but with 1, 2, 3, 4, or 5 substitutions in the framework regions of the VH sequence.

[0098] In certain embodiments, an anti-CD74 antibody comprises a VH and a VL comprising the amino acid sequences of the VH and VL of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56.

[0099] In certain embodiments, an anti-CD74 antibody comprises a VH CDR1, CDR2, and CDR3 comprising the amino acid sequences of the VH CDRs of any of the anti-CD74 antibodies provided herein as well as a VL CDR1, CDR2, and CDR3 comprising the amino acid sequences of the VL CDRs of any of the anti-CD74 antibodies provided herein, and also comprises a VH and a VL that are each at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the corresponding VH and VL of any of the anti-CD74 antibodies provided herein. In certain embodiments, the VH and the VL of the antibody differ from the VH and VL sequences shown in the Sequence Table due to 1, 2, 3, 4, or 5 amino acid substitutions in the framework regions of the sequences, such as 1, 2, 3, 4, or 5 conservative substitutions, or such as 1, 2, 3, 4 or 5 reversion substitutions.

[0100] In certain embodiments, an anti-CD74 antibody comprises a VH and a VL consisting of the amino acid sequence of the VH and VL of any of the anti-CD74 antibodies provided herein. In certain embodiments, an anti-CD74 antibody comprises a VH and a VL that each consist of the amino acid sequences of the VH and VL of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56.

[0101] An anti-CD74 antibody may comprise: (a) a VH comprising the amino acid sequence of the VH of antibody clone number 22 and a VL comprising the amino acid sequence of the VL of antibody clone number 22; or (b) a VH comprising the amino acid sequence of the VH of antibody clone number 3 and a VL comprising the amino acid sequence of the VL of antibody clone number 3; or (c) a VH comprising the amino acid sequence of the VH of antibody clone number 1 and a VL comprising the amino acid sequence of the VL of antibody clone number 1; or (d) a VH comprising the amino acid sequence of the VH of antibody clone number 41 and a VL comprising the amino acid sequence of the VL of antibody clone number 41; or (e) a VH comprising the amino acid sequence of the VH of antibody clone number 93 and a VL comprising the amino acid sequence of the VL of antibody clone number 93; or (f) a VH comprising the amino acid sequence of the VH of antibody clone number 95 and a VL comprising the amino acid sequence of the VL of antibody clone number 95; orAttorney Docket No.01245-0062-00PCT (g) a VH comprising the amino acid sequence of the VH of antibody clone number 4 and a VL comprising the amino acid sequence of the VL of antibody clone number 4; or (h) a VH comprising the amino acid sequence of the VH of antibody clone number 7 and a VL comprising the amino acid sequence of the VL of antibody clone number 7; or (i) a VH comprising the amino acid sequence of the VH of antibody clone number 53 and a VL comprising the amino acid sequence of the VL of antibody clone number 53; or (j) a VH comprising the amino acid sequence of the VH of antibody clone number 66 and a VL comprising the amino acid sequence of the VL of antibody clone number 66; or (k) a VH comprising the amino acid sequence of the VH of antibody clone number 68 and a VL comprising the amino acid sequence of the VL of antibody clone number 68; or (l) a VH comprising the amino acid sequence of the VH of antibody clone number 76 and a VL comprising the amino acid sequence of the VL of antibody clone number 76; or (m) a VH comprising the amino acid sequence of the VH of antibody clone number 77 and a VL comprising the amino acid sequence of the VL of antibody clone number 77; or (n) a VH comprising the amino acid sequence of the VH of antibody clone number 60 and a VL comprising the amino acid sequence of the VL of antibody clone number 60; or (o) a VH comprising the amino acid sequence of the VH of antibody clone number 61 and a VL comprising the amino acid sequence of the VL of antibody clone number 61; or (p) a VH comprising the amino acid sequence of the VH of antibody clone number 33 and a VL comprising the amino acid sequence of the VL of antibody clone number 33; or (q) a VH comprising the amino acid sequence of the VH of antibody clone number 49 and a VL comprising the amino acid sequence of the VL of antibody clone number 49; or (r) a VH comprising the amino acid sequence of the VH of antibody clone number 56 and a VL comprising the amino acid sequence of the VL of antibody clone number 56.

[0102] An anti-CD74 antibody may comprise: (a) a VH comprising the VH CDRs of the VH of antibody clone number 22, and a VL comprising the VL CDRs of antibody clone number 22, and VH and VL amino acid sequences that are at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the VH and VL of antibody clone number 22; or (b) a VH comprising the VH CDRs of the VH of antibody clone number 3, and a VL comprising the VL CDRs of antibody clone number 3, and VH and VL amino acid sequences that are at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the VH and VL of antibody clone number 3; orAttorney Docket No.01245-0062-00PCT (c) a VH comprising the VH CDRs of the VH of antibody clone number 1, and a VL comprising the VL CDRs of antibody clone number 1, and VH and VL amino acid sequences that are at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the VH and VL of antibody clone number 1; or (d) a VH comprising the VH CDRs of the VH of antibody clone number 41, and a VL comprising the VL CDRs of antibody clone number 41, and VH and VL amino acid sequences that are at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the VH and VL of antibody clone number 41; or (e) a VH comprising the VH CDRs of the VH of antibody clone number 93, and a VL comprising the VL CDRs of antibody clone number 93, and VH and VL amino acid sequences that are at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the VH and VL of antibody clone number 93; or (f) a VH comprising the VH CDRs of the VH of antibody clone number 95, and a VL comprising the VL CDRs of antibody clone number 95, and VH and VL amino acid sequences that are at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the VH and VL of antibody clone number 95; or (g) a VH comprising the VH CDRs of the VH of antibody clone number 4, and a VL comprising the VL CDRs of antibody clone number 4, and VH and VL amino acid sequences that are at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the VH and VL of antibody clone number 4; or (h) a VH comprising the VH CDRs of the VH of antibody clone number 7, and a VL comprising the VL CDRs of antibody clone number 7, and VH and VL amino acid sequences that are at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the VH and VL of antibody clone number 7; or (i) a VH comprising the VH CDRs of the VH of antibody clone number 53, and a VL comprising the VL CDRs of antibody clone number 53, and VH and VL amino acid sequences that are at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the VH and VL of antibody clone number 53; orAttorney Docket No.01245-0062-00PCT (j) a VH comprising the VH CDRs of the VH of antibody clone number 66, and a VL comprising the VL CDRs of antibody clone number 66, and VH and VL amino acid sequences that are at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the VH and VL of antibody clone number 66; or (k) a VH comprising the VH CDRs of the VH of antibody clone number 67, and a VL comprising the VL CDRs of antibody clone number 68, and VH and VL amino acid sequences that are at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the VH and VL of antibody clone number 68; or (l) a VH comprising the VH CDRs of the VH of antibody clone number 76, and a VL comprising the VL CDRs of antibody clone number 76, and VH and VL amino acid sequences that are at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the VH and VL of antibody clone number 76; or (m) a VH comprising the VH CDRs of the VH of antibody clone number 77, and a VL comprising the VL CDRs of antibody clone number 77, and VH and VL amino acid sequences that are at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the VH and VL of antibody clone number 77; or (n) a VH comprising the VH CDRs of the VH of antibody clone number 60, and a VL comprising the VL CDRs of antibody clone number 60, and VH and VL amino acid sequences that are at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the VH and VL of antibody clone number 60; or (o) a VH comprising the VH CDRs of the VH of antibody clone number 61, and a VL comprising the VL CDRs of antibody clone number 61, and VH and VL amino acid sequences that are at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the VH and VL of antibody clone number 61; or (p) a VH comprising the VH CDRs of the VH of antibody clone number 33, and a VL comprising the VL CDRs of antibody clone number 33, and VH and VL amino acid sequences that are at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the VH and VL of antibody clone number 33; orAttorney Docket No.01245-0062-00PCT (q) a VH comprising the VH CDRs of the VH of antibody clone number 49, and a VL comprising the VL CDRs of antibody clone number 49, and VH and VL amino acid sequences that are at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the VH and VL of antibody clone number 49; or (r) a VH comprising the VH CDRs of the VH of antibody clone number 56, and a VL comprising the VL CDRs of antibody clone number 56, and VH and VL amino acid sequences that are at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the VH and VL of antibody clone number 56.

[0103] In some of the above embodiments, the VH and / or VL may differ from the sequence of each of the species by the presence of 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, and / or insertions, and / or deletions, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 conservative substitutions. In some embodiments, the VH may comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 reversion substitutions.

[0104] An anti-CD74 antibody may comprise: (a) a VH consisting of the amino acid sequence of the VH of antibody clone number 22 and a VL consisting of the VL of antibody clone number 22; or (b) a VH consisting of the amino acid sequence of the VH of antibody clone number 3 and a VL consisting of the VL of antibody clone number 3; or (c) a VH consisting of the amino acid sequence of the VH of antibody clone number 1 and a VL consisting of the VL of antibody clone number 1; or (d) a VH consisting of the amino acid sequence of the VH of antibody clone number 41 and a VL consisting of the VL of antibody clone number 41; or (e) a VH consisting of the amino acid sequence of the VH of antibody clone number 93 and a VL consisting of the VL of antibody clone number 93; or (f) a VH consisting of the amino acid sequence of the VH of antibody clone number 95 and a VL consisting of the VL of antibody clone number 95; or (g) a VH consisting of the amino acid sequence of the VH of antibody clone number 4 and a VL consisting of the VL of antibody clone number 4; or (h) a VH consisting of the amino acid sequence of the VH of antibody clone number 7 and a VL consisting of the VL of antibody clone number 7; or (i) a VH consisting of the amino acid sequence of the VH of antibody clone number 53 and a VL consisting of the VL of antibody clone number 53; orAttorney Docket No.01245-0062-00PCT (j) a VH consisting of the amino acid sequence of the VH of antibody clone number 66 and a VL consisting of the VL of antibody clone number 66; or (k) a VH consisting of the amino acid sequence of the VH of antibody clone number 68 and a VL consisting of the VL of antibody clone number 68; or (l) a VH consisting of the amino acid sequence of the VH of antibody clone number 76 and a VL consisting of the VL of antibody clone number 76; or (m) a VH consisting of the amino acid sequence of the VH of antibody clone number 77 and a VL consisting of the VL of antibody clone number 77; or (n) a VH consisting of the amino acid sequence of the VH of antibody clone number 60 and a VL consisting of the VL of antibody clone number 60; or (o) a VH consisting of the amino acid sequence of the VH of antibody clone number 61 and a VL consisting of the VL of antibody clone number 61; or (p) a VH consisting of the amino acid sequence of the VH of antibody clone number 33 and a VL consisting of the VL of antibody clone number 33; or (q) a VH consisting of the amino acid sequence of the VH of antibody clone number 49 and a VL consisting of the VL of antibody clone number 49; or (r) a VH consisting of the amino acid sequence of the VH of antibody clone number 56 and a VL consisting of the VL of antibody clone number 56.

[0105] In certain embodiments, an anti-CD74 antibody comprises any of the variable regions and / or variable region CDRs 1-3 of the antibodies described above and elsewhere herein, such as in the Sequence Table.

[0106] In certain embodiments, an anti-CD74 antibody comprises a VH that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical the amino acid sequence of SEQ ID NO: 12 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 18. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of SEQ ID NO: 12 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of SEQ ID NO: 18. In certain embodiments, an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 12 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 18; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 2; (c) HCDR3 comprising theAttorney Docket No.01245-0062-00PCT amino acid sequence of SEQ ID NO: 3; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 4; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 5; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 6. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of SEQ ID NO: 12 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of SEQ ID NO: 18; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 2; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 3; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 4; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 5; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 6. In certain embodiments, an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 2; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 3; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 4; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 5; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 6. In certain embodiments, an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 2 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 2 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 3 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 3 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 4 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 4 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 5 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 5 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 6 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 6 with one or two amino acid substitutions. In some embodiments, the one or two amino acid substitutions are conservative amino acid substitutions. In some embodiments, the one or two amino acid substitutions are non-conservative amino acid substitutions.

[0107] In certain embodiments, an anti-CD74 antibody comprises a VH comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VH of clone number 22 and a VL comprising anAttorney Docket No.01245-0062-00PCT amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VL of clone number 22. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of clone 22 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of clone 22. In certain embodiments, an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 22 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 22; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 22. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of clone 22 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of clone 22; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 22. In certain embodiments, an anti-CD74 antibody comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 22. In certain embodiments, an anti-CD74 antibody comprises HCDR1 of clone 22 or HCDR1 of clone 22 with one or two amino acid substitutions, HCDR2 of clone 22 or HCDR2 of clone 22 with one or two amino acid substitutions, HCDR3 of clone 22 or HCDR3 of clone 22 with one or two amino acid substitutions, LCDR1 of clone 22 or LCDR1 of clone 22 with one or two amino acid substitutions, LCDR2 of clone 22 or LCDR2 of clone 22 with one or two amino acid substitutions, and LCDR3 of clone 22 or LCDR3 of clone 22 with one or two amino acid substitutions. In some embodiments, the one or two amino acid substitutions are conservative amino acid substitutions. In some embodiments, the one or two amino acid substitutions are non- conservative amino acid substitutions.

[0108] In certain embodiments, an anti-CD74 antibody comprises a VH that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical the amino acid sequence of SEQ ID NO: 112 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 118. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of SEQ ID NO: 112 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of SEQ ID NO: 118. In certain embodiments, an anti-Attorney Docket No.01245-0062-00PCT CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 112 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 118; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 101; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 102; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 103; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 104; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 105; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 106. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of SEQ ID NO: 112 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of SEQ ID NO: 118; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 101; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 102; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 103; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 104; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 105; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 106. In certain embodiments, an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 101; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 102; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 103; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 104; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 105; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 106. In certain embodiments, an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 101 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 101 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 102 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 102 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 103 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 103 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 104 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 104 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 105 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 105 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 106 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 106 with one or two amino acid substitutions. In some embodiments, the one or two amino acid substitutions are conservativeAttorney Docket No.01245-0062-00PCT amino acid substitutions. In some embodiments, the one or two amino acid substitutions are non- conservative amino acid substitutions.

[0109] In certain embodiments, an anti-CD74 antibody comprises a VH comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VH of clone number 3 and a VL comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VL of clone number 3. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of clone 3 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of clone 3. In certain embodiments, an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 3 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 3; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 3. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of clone 3 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of clone 3; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 3. In certain embodiments, an anti-CD74 antibody comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 3. In certain embodiments, an anti-CD74 antibody comprises HCDR1 of clone 3 or HCDR1 of clone 3 with one or two amino acid substitutions, HCDR2 of clone 3 or HCDR2 of clone 3 with one or two amino acid substitutions, HCDR3 of clone 3 or HCDR3 of clone 3 with one or two amino acid substitutions, LCDR1 of clone 3 or LCDR1 of clone 3 with one or two amino acid substitutions, LCDR2 of clone 3 or LCDR2 of clone 3 with one or two amino acid substitutions, and LCDR3 of clone 3 or LCDR3 of clone 3 with one or two amino acid substitutions. In some embodiments, the one or two amino acid substitutions are conservative amino acid substitutions. In some embodiments, the one or two amino acid substitutions are non-conservative amino acid substitutions.

[0110] In certain embodiments, an anti-CD74 antibody comprises a VH that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical the amino acid sequence of SEQ ID NO: 212 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%Attorney Docket No.01245-0062-00PCT identical to the amino acid sequence of SEQ ID NO: 218. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of SEQ ID NO: 212 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of SEQ ID NO: 218. In certain embodiments, an anti- CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 212 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 218; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 201; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 202; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 203; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 204; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 205; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 206. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of SEQ ID NO: 212 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of SEQ ID NO: 218; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 201; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 202; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 203; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 204; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 205; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 206. In certain embodiments, an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 201; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 202; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 203; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 204; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 205; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 206. In certain embodiments, an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 201 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 201 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 202 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 202 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 203 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 203 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 204 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 204 with one or two amino acidAttorney Docket No.01245-0062-00PCT substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 205 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 205 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 206 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 206 with one or two amino acid substitutions. In some embodiments, the one or two amino acid substitutions are conservative amino acid substitutions. In some embodiments, the one or two amino acid substitutions are non- conservative amino acid substitutions.

[0111] In certain embodiments, an anti-CD74 antibody comprises a VH comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VH of clone number 1 and a VL comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VL of clone number 1. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of clone 1 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of clone 1. In certain embodiments, an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 1 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 1; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 1. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of clone 1 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of clone 1; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 1. In certain embodiments, an anti-CD74 antibody comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 1. In certain embodiments, an anti-CD74 antibody comprises HCDR1 of clone 1 or HCDR1 of clone 1 with one or two amino acid substitutions, HCDR2 of clone 1 or HCDR2 of clone 1 with one or two amino acid substitutions, HCDR3 of clone 1 or HCDR3 of clone 1 with one or two amino acid substitutions, LCDR1 of clone 1 or LCDR1 of clone 1 with one or two amino acid substitutions, LCDR2 of clone 1 or LCDR2 of clone 1 with one or two amino acid substitutions, and LCDR3 of clone 1 or LCDR3 of clone 1 with one or two amino acid substitutions. In some embodiments, the one orAttorney Docket No.01245-0062-00PCT two amino acid substitutions are conservative amino acid substitutions. In some embodiments, the one or two amino acid substitutions are non-conservative amino acid substitutions.

[0112] In certain embodiments, an anti-CD74 antibody comprises a VH that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical the amino acid sequence of SEQ ID NO: 312 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 318. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of SEQ ID NO: 312 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of SEQ ID NO: 318. In certain embodiments, an anti- CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 312 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 318; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 301; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 302; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 303; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 304; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 305; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 306. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of SEQ ID NO: 312 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of SEQ ID NO: 318; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 301; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 302; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 303; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 304; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 305; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 306. In certain embodiments, an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 301; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 302; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 303; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 304; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 305; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 306. In certain embodiments, an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 301 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 301 with one or two amino acidAttorney Docket No.01245-0062-00PCT substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 302 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 302 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 303 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 303 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 304 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 304 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 305 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 305 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 306 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 306 with one or two amino acid substitutions. In some embodiments, the one or two amino acid substitutions are conservative amino acid substitutions. In some embodiments, the one or two amino acid substitutions are non- conservative amino acid substitutions.

[0113] In certain embodiments, an anti-CD74 antibody comprises a VH comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VH of clone number 41 and a VL comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VL of clone number 41. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of clone 41 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of clone 41. In certain embodiments, an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 41 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 41; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 41. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of clone 41 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of clone 41; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 41. In certain embodiments, an anti-CD74 antibody comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 41. In certain embodiments, an anti-CD74 antibody comprises HCDR1 of clone 41 or HCDR1 of cloneAttorney Docket No.01245-0062-00PCT 41 with one or two amino acid substitutions, HCDR2 of clone 41 or HCDR2 of clone 41 with one or two amino acid substitutions, HCDR3 of clone 41 or HCDR3 of clone 41 with one or two amino acid substitutions, LCDR1 of clone 41 or LCDR1 of clone 41 with one or two amino acid substitutions, LCDR2 of clone 41 or LCDR2 of clone 41 with one or two amino acid substitutions, and LCDR3 of clone 41 or LCDR3 of clone 41 with one or two amino acid substitutions. In some embodiments, the one or two amino acid substitutions are conservative amino acid substitutions. In some embodiments, the one or two amino acid substitutions are non- conservative amino acid substitutions.

[0114] In certain embodiments, an anti-CD74 antibody comprises a VH that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical the amino acid sequence of SEQ ID NO: 512 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 518. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of SEQ ID NO: 512 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of SEQ ID NO: 518. In certain embodiments, an anti- CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 512 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 518; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 501; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 502; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 503; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 504; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 505; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 506. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of SEQ ID NO: 512 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of SEQ ID NO: 518; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 501; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 502; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 503; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 504; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 505; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 506. In certain embodiments, an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 501; (b) HCDR2Attorney Docket No.01245-0062-00PCT comprising the amino acid sequence of SEQ ID NO: 502; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 503; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 504; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 505; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 506. In certain embodiments, an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 501 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 501 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 502 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 502 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 503 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 503 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 104 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 504 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 505 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 505 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 506 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 506 with one or two amino acid substitutions. In some embodiments, the one or two amino acid substitutions are conservative amino acid substitutions. In some embodiments, the one or two amino acid substitutions are non- conservative amino acid substitutions.

[0115] In certain embodiments, an anti-CD74 antibody comprises a VH comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VH of clone number 93 and a VL comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VL of clone number 93. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of clone 93 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of clone 93. In certain embodiments, an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 93 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 93; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 93. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10Attorney Docket No.01245-0062-00PCT amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of clone 93 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of clone 93; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 93. In certain embodiments, an anti-CD74 antibody comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 93. In certain embodiments, an anti-CD74 antibody comprises HCDR1 of clone 93 or HCDR1 of clone 93 with one or two amino acid substitutions, HCDR2 of clone 93 or HCDR2 of clone 93 with one or two amino acid substitutions, HCDR3 of clone 93 or HCDR3 of clone 93 with one or two amino acid substitutions, LCDR1 of clone 93 or LCDR1 of clone 93 with one or two amino acid substitutions, LCDR2 of clone 93 or LCDR2 of clone 93 with one or two amino acid substitutions, and LCDR3 of clone 93 or LCDR3 of clone 93 with one or two amino acid substitutions. In some embodiments, the one or two amino acid substitutions are conservative amino acid substitutions. In some embodiments, the one or two amino acid substitutions are non- conservative amino acid substitutions.

[0116] In certain embodiments, an anti-CD74 antibody comprises a VH that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical the amino acid sequence of SEQ ID NO: 612 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 618. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of SEQ ID NO: 612 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of SEQ ID NO: 618. In certain embodiments, an anti- CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 612 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 618; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 601; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 602; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 603; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 604; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 605; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 606. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of SEQ ID NO: 612 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of SEQ ID NO: 618; and (a)Attorney Docket No.01245-0062-00PCT HCDR1 comprising the amino acid sequence of SEQ ID NO: 601; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 602; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 603; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 604; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 605; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 606. In certain embodiments, an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 601; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 602; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 603; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 604; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 605; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 606. In certain embodiments, an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 601 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 601 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 602 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 602 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 603 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 603 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 604 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 604 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 605 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 605 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 606 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 606 with one or two amino acid substitutions. In some embodiments, the one or two amino acid substitutions are conservative amino acid substitutions. In some embodiments, the one or two amino acid substitutions are non- conservative amino acid substitutions.

[0117] In certain embodiments, an anti-CD74 antibody comprises a VH comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VH of clone number 95 and a VL comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VL of clone number 95. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of clone 95 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletionsAttorney Docket No.01245-0062-00PCT compared to the amino acid sequence of clone 95. In certain embodiments, an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 95 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 95; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 95. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of clone 95 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of clone 95; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 95. In certain embodiments, an anti-CD74 antibody comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 95. In certain embodiments, an anti-CD74 antibody comprises HCDR1 of clone 95 or HCDR1 of clone 95 with one or two amino acid substitutions, HCDR2 of clone 95 or HCDR2 of clone 95 with one or two amino acid substitutions, HCDR3 of clone 95 or HCDR3 of clone 95 with one or two amino acid substitutions, LCDR1 of clone 95 or LCDR1 of clone 95 with one or two amino acid substitutions, LCDR2 of clone 95 or LCDR2 of clone 95 with one or two amino acid substitutions, and LCDR3 of clone 95 or LCDR3 of clone 95 with one or two amino acid substitutions. In some embodiments, the one or two amino acid substitutions are conservative amino acid substitutions. In some embodiments, the one or two amino acid substitutions are non- conservative amino acid substitutions.

[0118] In certain embodiments, an anti-CD74 antibody comprises a VH that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical the amino acid sequence of SEQ ID NO: 712 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 718. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of SEQ ID NO: 712 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of SEQ ID NO: 718. In certain embodiments, an anti- CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 712 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 718; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 701; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 702; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 703; (d) LCDR1 comprising the amino acidAttorney Docket No.01245-0062-00PCT sequence of SEQ ID NO: 704; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 705; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 706. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of SEQ ID NO: 712 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of SEQ ID NO: 718; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 701; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 702; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 703; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 704; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 705; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 706. In certain embodiments, an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 701; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 702; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 703; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 704; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 705; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 706. In certain embodiments, an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 701 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 701 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 702 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 702 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 703 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 703 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 704 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 704 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 705 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 705 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 706 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 706 with one or two amino acid substitutions. In some embodiments, the one or two amino acid substitutions are conservative amino acid substitutions. In some embodiments, the one or two amino acid substitutions are non- conservative amino acid substitutions.

[0119] In certain embodiments, an anti-CD74 antibody comprises a VH comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VH of clone number 4 and a VL comprising an aminoAttorney Docket No.01245-0062-00PCT acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VL of clone number 4. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of clone 4 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of clone 4. In certain embodiments, an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 4 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 4; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 4. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of clone 4 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of clone 4; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 4. In certain embodiments, an anti-CD74 antibody comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 4. In certain embodiments, an anti-CD74 antibody comprises HCDR1 of clone 4 or HCDR1 of clone 4 with one or two amino acid substitutions, HCDR2 of clone 4 or HCDR2 of clone 4 with one or two amino acid substitutions, HCDR3 of clone 4 or HCDR3 of clone 4 with one or two amino acid substitutions, LCDR1 of clone 4 or LCDR1 of clone 4 with one or two amino acid substitutions, LCDR2 of clone 4 or LCDR2 of clone 4 with one or two amino acid substitutions, and LCDR3 of clone 4 or LCDR3 of clone 4 with one or two amino acid substitutions. In some embodiments, the one or two amino acid substitutions are conservative amino acid substitutions. In some embodiments, the one or two amino acid substitutions are non-conservative amino acid substitutions.

[0120] In certain embodiments, an anti-CD74 antibody comprises a VH that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical the amino acid sequence of SEQ ID NO: 812 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 818. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of SEQ ID NO: 812 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of SEQ ID NO: 818. In certain embodiments, an anti- CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%,Attorney Docket No.01245-0062-00PCT 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 812 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 818; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 801; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 802; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 803; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 804; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 805; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 806. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of SEQ ID NO: 812 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of SEQ ID NO: 818; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 801; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 802; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 803; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 804; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 805; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 806. In certain embodiments, an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 801; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 802; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 803; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 804; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 805; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 806. In certain embodiments, an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 801 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 801 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 802 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 802 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 803 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 803 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 804 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 804 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 805 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 805 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 806 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 806 with one or two amino acid substitutions. In some embodiments, the one or two amino acid substitutions are conservativeAttorney Docket No.01245-0062-00PCT amino acid substitutions. In some embodiments, the one or two amino acid substitutions are non- conservative amino acid substitutions.

[0121] In certain embodiments, an anti-CD74 antibody comprises a VH comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VH of clone number 7 and a VL comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VL of clone number 7. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of clone 7 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of clone 7. In certain embodiments, an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 7 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 7; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 7. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of clone 7 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of clone 7; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 7. In certain embodiments, an anti-CD74 antibody comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 7. In certain embodiments, an anti-CD74 antibody comprises HCDR1 of clone 7 or HCDR1 of clone 7 with one or two amino acid substitutions, HCDR2 of clone 7 or HCDR2 of clone 7 with one or two amino acid substitutions, HCDR3 of clone 7 or HCDR3 of clone 7 with one or two amino acid substitutions, LCDR1 of clone 7 or LCDR1 of clone 7 with one or two amino acid substitutions, LCDR2 of clone 7 or LCDR2 of clone 7 with one or two amino acid substitutions, and LCDR3 of clone 7 or LCDR3 of clone 7 with one or two amino acid substitutions. In some embodiments, the one or two amino acid substitutions are conservative amino acid substitutions. In some embodiments, the one or two amino acid substitutions are non-conservative amino acid substitutions.

[0122] In certain embodiments, an anti-CD74 antibody comprises a VH that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical the amino acid sequence of SEQ ID NO: 912 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%Attorney Docket No.01245-0062-00PCT identical to the amino acid sequence of SEQ ID NO: 918. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of SEQ ID NO: 912 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of SEQ ID NO: 918. In certain embodiments, an anti- CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 912 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 918; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 901; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 902; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 903; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 904; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 905; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 906. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of SEQ ID NO: 912 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of SEQ ID NO: 918; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 901; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 902; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 903; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 904; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 905; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 906. In certain embodiments, an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 901; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 902; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 903; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 904; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 905; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 906. In certain embodiments, an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 901 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 901 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 902 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 902 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 903 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 903 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 904 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 904 with one or two amino acidAttorney Docket No.01245-0062-00PCT substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 905 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 905 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 906 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 906 with one or two amino acid substitutions. In some embodiments, the one or two amino acid substitutions are conservative amino acid substitutions. In some embodiments, the one or two amino acid substitutions are non- conservative amino acid substitutions.

[0123] In certain embodiments, an anti-CD74 antibody comprises a VH comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VH of clone number 53 and a VL comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VL of clone number 53. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of clone 53 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of clone 53. In certain embodiments, an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 53 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 53; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 53. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of clone 53 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of clone 53; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 53. In certain embodiments, an anti-CD74 antibody comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 53. In certain embodiments, an anti-CD74 antibody comprises HCDR1 of clone 53 or HCDR1 of clone 53 with one or two amino acid substitutions, HCDR2 of clone 53 or HCDR2 of clone 53 with one or two amino acid substitutions, HCDR3 of clone 53 or HCDR3 of clone 53 with one or two amino acid substitutions, LCDR1 of clone 53 or LCDR1 of clone 53 with one or two amino acid substitutions, LCDR2 of clone 53 or LCDR2 of clone 53 with one or two amino acid substitutions, and LCDR3 of clone 53 or LCDR3 of clone 53 with one or two amino acid substitutions. In some embodiments, the one or two amino acid substitutions are conservativeAttorney Docket No.01245-0062-00PCT amino acid substitutions. In some embodiments, the one or two amino acid substitutions are non- conservative amino acid substitutions.

[0124] In certain embodiments, an anti-CD74 antibody comprises a VH that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical the amino acid sequence of SEQ ID NO: 1012 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1018. In certain embodiments, an anti- CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of SEQ ID NO: 1012 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of SEQ ID NO: 1018. In certain embodiments, an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1012 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1018; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1001; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1002; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1003; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1004; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1005; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1006. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of SEQ ID NO: 1012 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of SEQ ID NO: 1018; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1001; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1002; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1003; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1004; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1005; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1006. In certain embodiments, an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1001; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1002; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1003; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1004; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1005; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1006. In certain embodiments, an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1001 or HCDR1 comprising the amino acid sequenceAttorney Docket No.01245-0062-00PCT of SEQ ID NO: 1001 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1002 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1002 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1003 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1003 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1004 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1004 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1005 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1005 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1006 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1006 with one or two amino acid substitutions. In some embodiments, the one or two amino acid substitutions are conservative amino acid substitutions. In some embodiments, the one or two amino acid substitutions are non-conservative amino acid substitutions.

[0125] In certain embodiments, an anti-CD74 antibody comprises a VH comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VH of clone number 66 and a VL comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VL of clone number 66. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of clone 66 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of clone 66. In certain embodiments, an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 66 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 66; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 66. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of clone 66 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of clone 66; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 66. In certain embodiments, an anti-CD74 antibody comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 66. In certain embodiments, an anti-CD74 antibody comprises HCDR1 of clone 66 or HCDR1 of cloneAttorney Docket No.01245-0062-00PCT 66 with one or two amino acid substitutions, HCDR2 of clone 66 or HCDR2 of clone 66 with one or two amino acid substitutions, HCDR3 of clone 66 or HCDR3 of clone 66 with one or two amino acid substitutions, LCDR1 of clone 66 or LCDR1 of clone 66 with one or two amino acid substitutions, LCDR2 of clone 66 or LCDR2 of clone 66 with one or two amino acid substitutions, and LCDR3 of clone 66 or LCDR3 of clone 66 with one or two amino acid substitutions. In some embodiments, the one or two amino acid substitutions are conservative amino acid substitutions. In some embodiments, the one or two amino acid substitutions are non- conservative amino acid substitutions.

[0126] In certain embodiments, an anti-CD74 antibody comprises a VH that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical the amino acid sequence of SEQ ID NO: 1112 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1118. In certain embodiments, an anti- CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of SEQ ID NO: 1112 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of SEQ ID NO: 1118. In certain embodiments, an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1112 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1118; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1101; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1102; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1103; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1104; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1105; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1106. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of SEQ ID NO: 1112 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of SEQ ID NO: 1118; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1101; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1102; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1103; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1104; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1105; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1106. In certain embodiments, an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acidAttorney Docket No.01245-0062-00PCT sequence of SEQ ID NO: 1101; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1102; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1103; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1104; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1105; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1106. In certain embodiments, an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1101 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1101 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1102 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1102 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1103 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1103 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1104 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1104 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1105 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1105 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1106 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1106 with one or two amino acid substitutions. In some embodiments, the one or two amino acid substitutions are conservative amino acid substitutions. In some embodiments, the one or two amino acid substitutions are non-conservative amino acid substitutions.

[0127] In certain embodiments, an anti-CD74 antibody comprises a VH comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VH of clone number 68 and a VL comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VL of clone number 68. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of clone 68 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of clone 68. In certain embodiments, an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 68 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 68; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 68. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10Attorney Docket No.01245-0062-00PCT amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of clone 68 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of clone 68; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 68. In certain embodiments, an anti-CD74 antibody comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 68. In certain embodiments, an anti-CD74 antibody comprises HCDR1 of clone 68 or HCDR1 of clone 68 with one or two amino acid substitutions, HCDR2 of clone 68 or HCDR2 of clone 68 with one or two amino acid substitutions, HCDR3 of clone 68 or HCDR3 of clone 68 with one or two amino acid substitutions, LCDR1 of clone 68 or LCDR1 of clone 68 with one or two amino acid substitutions, LCDR2 of clone 68 or LCDR2 of clone 68 with one or two amino acid substitutions, and LCDR3 of clone 68 or LCDR3 of clone 68 with one or two amino acid substitutions. In some embodiments, the one or two amino acid substitutions are conservative amino acid substitutions. In some embodiments, the one or two amino acid substitutions are non- conservative amino acid substitutions.

[0128] In certain embodiments, an anti-CD74 antibody comprises a VH that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical the amino acid sequence of SEQ ID NO: 1212 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1218. In certain embodiments, an anti- CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of SEQ ID NO: 1212 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of SEQ ID NO: 1218. In certain embodiments, an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1212 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1218; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1201; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1202; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1203; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1204; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1205; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1206. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of SEQ ID NO: 1212 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence ofAttorney Docket No.01245-0062-00PCT SEQ ID NO: 1218; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1201; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1202; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1203; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1204; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1205; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1206. In certain embodiments, an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1201; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1202; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1203; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1204; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1205; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1206. In certain embodiments, an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1201 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1201 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1202 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1202 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1203 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1203 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1204 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1204 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1205 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1205 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1206 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1206 with one or two amino acid substitutions. In some embodiments, the one or two amino acid substitutions are conservative amino acid substitutions. In some embodiments, the one or two amino acid substitutions are non-conservative amino acid substitutions.

[0129] In certain embodiments, an anti-CD74 antibody comprises a VH comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VH of clone number 76 and a VL comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VL of clone number 76. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of clone 76 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletionsAttorney Docket No.01245-0062-00PCT compared to the amino acid sequence of clone 76. In certain embodiments, an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 76 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 76; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 76. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of clone 76 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of clone 76; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 76. In certain embodiments, an anti-CD74 antibody comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 76. In certain embodiments, an anti-CD74 antibody comprises HCDR1 of clone 76 or HCDR1 of clone 76 with one or two amino acid substitutions, HCDR2 of clone 76 or HCDR2 of clone 76 with one or two amino acid substitutions, HCDR3 of clone 76 or HCDR3 of clone 76 with one or two amino acid substitutions, LCDR1 of clone 76 or LCDR1 of clone 76 with one or two amino acid substitutions, LCDR2 of clone 76 or LCDR2 of clone 76 with one or two amino acid substitutions, and LCDR3 of clone 76 or LCDR3 of clone 76 with one or two amino acid substitutions. In some embodiments, the one or two amino acid substitutions are conservative amino acid substitutions. In some embodiments, the one or two amino acid substitutions are non- conservative amino acid substitutions.

[0130] In certain embodiments, an anti-CD74 antibody comprises a VH that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical the amino acid sequence of SEQ ID NO: 1312 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1318. In certain embodiments, an anti- CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of SEQ ID NO: 1312 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of SEQ ID NO: 1318. In certain embodiments, an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1312 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1318; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1301; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1302; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1303; (d) LCDR1Attorney Docket No.01245-0062-00PCT comprising the amino acid sequence of SEQ ID NO: 1304; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1305; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1306. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of SEQ ID NO: 1312 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of SEQ ID NO: 1318; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1301; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1302; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1303; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1304; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1305; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1306. In certain embodiments, an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1301; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1302; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1303; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1304; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1305; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1306. In certain embodiments, an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1301 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1301 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1302 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1302 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1303 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1303 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1304 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1304 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1305 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1305 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1306 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1306 with one or two amino acid substitutions. In some embodiments, the one or two amino acid substitutions are conservative amino acid substitutions. In some embodiments, the one or two amino acid substitutions are non-conservative amino acid substitutions.

[0131] In certain embodiments, an anti-CD74 antibody comprises a VH comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VH of clone number 77 and a VL comprising anAttorney Docket No.01245-0062-00PCT amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VL of clone number 77. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of clone 77 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of clone 77. In certain embodiments, an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 77 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 77; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 77. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of clone 77 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of clone 77; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 77. In certain embodiments, an anti-CD74 antibody comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 77. In certain embodiments, an anti-CD74 antibody comprises HCDR1 of clone 77 or HCDR1 of clone 77 with one or two amino acid substitutions, HCDR2 of clone 77 or HCDR2 of clone 77 with one or two amino acid substitutions, HCDR3 of clone 77 or HCDR3 of clone 77 with one or two amino acid substitutions, LCDR1 of clone 77 or LCDR1 of clone 77 with one or two amino acid substitutions, LCDR2 of clone 77 or LCDR2 of clone 77 with one or two amino acid substitutions, and LCDR3 of clone 77 or LCDR3 of clone 77 with one or two amino acid substitutions. In some embodiments, the one or two amino acid substitutions are conservative amino acid substitutions. In some embodiments, the one or two amino acid substitutions are non- conservative amino acid substitutions.

[0132] In certain embodiments, an anti-CD74 antibody comprises a VH that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical the amino acid sequence of SEQ ID NO: 1412 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1418. In certain embodiments, an anti- CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of SEQ ID NO: 1412 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of SEQ ID NO: 1418. In certainAttorney Docket No.01245-0062-00PCT embodiments, an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1412 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1418; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1401; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1402; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1403; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1404; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1405; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1406. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of SEQ ID NO: 1412 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of SEQ ID NO: 1418; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1401; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1402; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1403; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1404; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1405; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1406. In certain embodiments, an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1401; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1402; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1403; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1404; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1405; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1406. In certain embodiments, an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1401 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1401 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1402 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1402 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1403 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1403 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1404 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1404 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1405 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1405 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1406 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1406 with one or two amino acid substitutions. In some embodiments, the one or two amino acid substitutions areAttorney Docket No.01245-0062-00PCT conservative amino acid substitutions. In some embodiments, the one or two amino acid substitutions are non-conservative amino acid substitutions.

[0133] In certain embodiments, an anti-CD74 antibody comprises a VH comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VH of clone number 60 and a VL comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VL of clone number 60. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of clone 60 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of clone 60. In certain embodiments, an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 60 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 60; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 60. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of clone 60 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of clone 60; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 60. In certain embodiments, an anti-CD74 antibody comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 60. In certain embodiments, an anti-CD74 antibody comprises HCDR1 of clone 60 or HCDR1 of clone 60 with one or two amino acid substitutions, HCDR2 of clone 60 or HCDR2 of clone 60 with one or two amino acid substitutions, HCDR3 of clone 60 or HCDR3 of clone 60 with one or two amino acid substitutions, LCDR1 of clone 60 or LCDR1 of clone 60 with one or two amino acid substitutions, LCDR2 of clone 60 or LCDR2 of clone 60 with one or two amino acid substitutions, and LCDR3 of clone 60 or LCDR3 of clone 60 with one or two amino acid substitutions. In some embodiments, the one or two amino acid substitutions are conservative amino acid substitutions. In some embodiments, the one or two amino acid substitutions are non- conservative amino acid substitutions.

[0134] In certain embodiments, an anti-CD74 antibody comprises a VH that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical the amino acid sequence of SEQ ID NO:Attorney Docket No.01245-0062-00PCT 1512 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1518. In certain embodiments, an anti- CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of SEQ ID NO: 1512 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of SEQ ID NO: 1518. In certain embodiments, an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1512 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1518; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1501; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1502; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1503; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1504; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1505; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1506. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of SEQ ID NO: 1512 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of SEQ ID NO: 1518; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1501; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1502; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1503; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1504; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1505; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1506. In certain embodiments, an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1501; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1502; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1503; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1504; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1505; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1506. In certain embodiments, an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1501 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1501 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1502 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1502 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1503 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1503 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acidAttorney Docket No.01245-0062-00PCT sequence of SEQ ID NO: 1504 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1504 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1505 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1505 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1506 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1506 with one or two amino acid substitutions. In some embodiments, the one or two amino acid substitutions are conservative amino acid substitutions. In some embodiments, the one or two amino acid substitutions are non-conservative amino acid substitutions.

[0135] In certain embodiments, an anti-CD74 antibody comprises a VH comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VH of clone number 61 and a VL comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VL of clone number 61. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of clone 61 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of clone 61. In certain embodiments, an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 61 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 61; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 61. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of clone 61 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of clone 61; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 61. In certain embodiments, an anti-CD74 antibody comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 61. In certain embodiments, an anti-CD74 antibody comprises HCDR1 of clone 61 or HCDR1 of clone 61 with one or two amino acid substitutions, HCDR2 of clone 61 or HCDR2 of clone 61 with one or two amino acid substitutions, HCDR3 of clone 61 or HCDR3 of clone 61 with one or two amino acid substitutions, LCDR1 of clone 61 or LCDR1 of clone 61 with one or two amino acid substitutions, LCDR2 of clone 61 or LCDR2 of clone 61 with one or two amino acid substitutions, and LCDR3 of clone 61 or LCDR3 of clone 61 with one or two amino acidAttorney Docket No.01245-0062-00PCT substitutions. In some embodiments, the one or two amino acid substitutions are conservative amino acid substitutions. In some embodiments, the one or two amino acid substitutions are non- conservative amino acid substitutions.

[0136] In certain embodiments, an anti-CD74 antibody comprises a VH that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical the amino acid sequence of SEQ ID NO: 1612 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1618. In certain embodiments, an anti- CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of SEQ ID NO: 1612 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of SEQ ID NO: 1618. In certain embodiments, an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1612 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1618; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1601; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1602; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1603; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1604; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1605; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1606. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of SEQ ID NO: 1612 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of SEQ ID NO: 1618; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1601; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1602; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1603; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1604; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1605; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1606. In certain embodiments, an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1601; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1602; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1603; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1604; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1605; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1606. In certain embodiments, an anti-CD74 antibody comprises (a) HCDR1 comprisingAttorney Docket No.01245-0062-00PCT the amino acid sequence of SEQ ID NO: 1601 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1601 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1602 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1602 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1603 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1603 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1604 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1604 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1605 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1605 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1606 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1606 with one or two amino acid substitutions. In some embodiments, the one or two amino acid substitutions are conservative amino acid substitutions. In some embodiments, the one or two amino acid substitutions are non-conservative amino acid substitutions.

[0137] In certain embodiments, an anti-CD74 antibody comprises a VH comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VH of clone number 33 and a VL comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VL of clone number 33. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of clone 33 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to the amino acid sequence of clone 33. In certain embodiments, an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 33 and a VL is at l...

Claims

Attorney Docket No.01245-0062-00PCT WHAT IS CLAIMED IS:

1. An isolated antibody that binds human CD74, the antibody comprising: i) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 2; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 3; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 4; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 5; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 6; or ii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 101; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 102; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 103; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 104; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 105; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 106; or iii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 201; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 202; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 203; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 204; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 205; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 206; or iv) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 301; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 302; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 303; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 304; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 305; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 306; or v) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 501; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 502; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 503; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 504; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 505; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 506; or vi) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 601; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 602; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 603; (d) LCDR1 comprising the aminoAttorney Docket No.01245-0062-00PCT acid sequence of SEQ ID NO: 604; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 605; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 606; or vii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 701; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 702; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 703; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 704; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 705; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 706; or viii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 801; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 802; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 803; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 804; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 805; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 806; or ix) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 901; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 902; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 903; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 904; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 905; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 906; or x) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1001; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1002; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1003; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1004; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1005; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1006; or xi) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1101; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1102; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1103; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1104; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1105; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1106; or xii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1201; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1202; (c) HCDR3Attorney Docket No.01245-0062-00PCT comprising the amino acid sequence of SEQ ID NO: 1203; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1204; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1205; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1206; or xiii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1301; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1302; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1303; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1304; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1305; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1306; or xiv) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1401; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1402; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1403; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1404; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1405; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1406; or xv) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1501; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1502; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1503; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1504; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1505; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1506; or xvi) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1601; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1602; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1603; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1604; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1605; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1606; or xvii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1701; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1702; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1703; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1704; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1705; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1706; orAttorney Docket No.01245-0062-00PCT xviii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1801; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1802; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1803; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1804; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1805; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1806.

2. An isolated antibody that binds human CD74, the antibody comprising: i) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 2 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 2 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 3 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 3 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 4 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 4 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 5 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 5 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 6 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 6 with one or two amino acid substitutions; or ii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 101 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 101 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 102 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 102 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 103 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 103 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 104 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 104 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 105 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 105 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 106 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 106 with one or two amino acid substitutions; orAttorney Docket No.01245-0062-00PCT iii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 201 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 201 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 202 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 202 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 203 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 203 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 204 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 204 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 205 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 205 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 206 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 206 with one or two amino acid substitutions; or iv) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 301 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 301 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 302 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 302 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 303 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 303 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 304 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 304 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 305 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 305 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 306 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 306 with one or two amino acid substitutions; or v) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 501 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 501 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 502 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 502 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 503 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 503 with one or two amino acid substitutions; (d) LCDR1Attorney Docket No.01245-0062-00PCT comprising the amino acid sequence of SEQ ID NO: 504 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 504 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 505 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 505 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 506 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 506 with one or two amino acid substitutions; or vi) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 601 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 601 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 602 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 602 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 603 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 603 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 604 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 604 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 605 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 605 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 606 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 606 with one or two amino acid substitutions; or vii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 701 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 701 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 702 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 702 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 703 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 703 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 704 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 704 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 705 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 705 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 706 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 706 with one or two amino acid substitutions; orAttorney Docket No.01245-0062-00PCT viii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 801 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 801 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 802 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 802 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 803 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 803 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 804 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 804 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 805 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 805 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 806 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 806 with one or two amino acid substitutions; or ix) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 901 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 901 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 902 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 902 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 903 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 903 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 904 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 904 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 905 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 905 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 906 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 906 with one or two amino acid substitutions; or x) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1001 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1001 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1002 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1002 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1003 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1003 with one or two amino acid substitutions; (d) LCDR1Attorney Docket No.01245-0062-00PCT comprising the amino acid sequence of SEQ ID NO: 1004 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1004 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1005 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1005 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1006 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1006 with one or two amino acid substitutions; or xi) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1101 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1101 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1102 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1102 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1103 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1103 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1104 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1104 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1105 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1105 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1106 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1106 with one or two amino acid substitutions; or xii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1201 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1201 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1202 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1202 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1203 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1203 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1204 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1204 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1205 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1205 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1206 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1206 with one or two amino acid substitutions; orAttorney Docket No.01245-0062-00PCT xiii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1301 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1301 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1302 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1302 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1303 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1303 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1304 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1304 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1305 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1305 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1306 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1306 with one or two amino acid substitutions; or xiv) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1401 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1401 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1402 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1402 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1403 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1403 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1404 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1404 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1405 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1405 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1406 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1406 with one or two amino acid substitutions; or xv) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1501 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1501 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1502 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1502 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1503 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1503 with one or two amino acid substitutions; (d) LCDR1Attorney Docket No.01245-0062-00PCT comprising the amino acid sequence of SEQ ID NO: 1504 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1504 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1505 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1505 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1506 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1506 with one or two amino acid substitutions; or xvi) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1601 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1601 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1602 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1602 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1603 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1603 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1604 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1604 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1605 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1605 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1606 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1606 with one or two amino acid substitutions; or xvii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1701 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1701 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1702 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1702 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1703 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1703 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1704 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1704 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1705 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1705 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1706 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1706 with one or two amino acid substitutions; orAttorney Docket No.01245-0062-00PCT xviii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1801 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1801 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1802 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1802 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1803 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1803 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1804 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1804 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1805 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1805 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1806 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1806 with one or two amino acid substitutions.

3. The isolated antibody of claim 1 or claim 2, wherein the antibody comprises: i) the CDRs of claim 1.i) and further comprises a heavy chain variable region (VH) that is at least 90% identical to the amino acid sequence of SEQ ID NO: 12; or ii) the CDRs of claim 1.ii) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 112; or iii) the CDRs of claim 1.iii) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 212; or iv) the CDRs of claim 1.iv) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 312; or v) the CDRs of claim 1.v) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 512; or vi) the CDRs of claim 1.vi) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 612; or vii) the CDRs of claim 1.vii) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 712; or viii) the CDRs of claim 1.viii) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 812; or ix) the CDRs of claim 1.ix) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 912; or x) the CDRs of claim 1.x) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1012; orAttorney Docket No.01245-0062-00PCT xi) the CDRs of claim 1.xi) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1112; or xii) the CDRs of claim 1.xii) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1212; or xiii) the CDRs of claim 1.xiii) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1312; or xiv) the CDRs of claim 1.xiv) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1412; or xv) the CDRs of claim 1.xv) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1512; or xvi) the CDRs of claim 1.xvi) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1612; or xvii) the CDRs of claim 1.xvii) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1712; or xviii) the CDRs of claim 1.xviii) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1812.

4. The isolated antibody of any one of claims 1-3, wherein the antibody comprises: i) the CDRs of claim 1.i) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 12; or ii) the CDRs of claim 1.ii) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 112; or iii) the CDRs of claim 1.iii) and further comprises a comprising the amino acid sequence of SEQ ID NO: 212; or iv) the CDRs of claim 1.iv) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 312; or v) the CDRs of claim 1.v) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 512; or vi) the CDRs of claim 1.vi) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 612; or vii) the CDRs of claim 1.vii) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 712; or viii) the CDRs of claim 1.viii) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 812; or ix) the CDRs of claim 1.ix) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 912; orAttorney Docket No.01245-0062-00PCT x) the CDRs of claim 1.x) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 1012; or xi) the CDRs of claim 1.xi) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 1112; or xii) the CDRs of claim 1.xii) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 1212; or xiii) the CDRs of claim 1.xiii) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 1312; or xiv) the CDRs of claim 1.xiv) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 1412; or xv) the CDRs of claim 1.xv) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 1512; or xvi) the CDRs of claim 1.xvi) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 1612; or xvii) the CDRs of claim 1.xvii) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 1712; or xviii) the CDRs of claim 1.xviii) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 1812.

5. The isolated antibody of any one of claims 1-4, wherein the antibody comprises: i) the CDRs of claim 1.i) and further comprises a light chain variable region (VL) that is at least 90% identical to the amino acid sequence of SEQ ID NO: 18; or ii) the CDRs of claim 1.ii) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 118; or iii) the CDRs of claim 1.iii) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 218; or iv) the CDRs of claim 1.iv) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 318; or v) the CDRs of claim 1.v) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 518; or vi) the CDRs of claim 1.vi) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 618; or vii) the CDRs of claim 1.vii) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 718; or viii) the CDRs of claim 1.viii) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 818; orAttorney Docket No.01245-0062-00PCT ix) the CDRs of claim 1.ix) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 918; or x) the CDRs of claim 1.x) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1018; or xi) the CDRs of claim 1.xi) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1118; or xii) the CDRs of claim 1.xii) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1218; or xiii) the CDRs of claim 1.xiii) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1318; or xiv) the CDRs of claim 1.xiv) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1418; or xv) the CDRs of claim 1.xv) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1518; or xvi) the CDRs of claim 1.xvi) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1618; or xvii) the CDRs of claim 1.xvii) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1718; or xviii) the CDRs of claim 1.xviii) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1818.

6. The isolated antibody of any one of claims 1-5, wherein the antibody comprises: i) the CDRs of claim 1.i) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 18; or ii) the CDRs of claim 1.ii) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 118; or iii) the CDRs of claim 1.iii) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 218; or iv) the CDRs of claim 1.iv) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 318; or v) the CDRs of claim 1.v) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 518; or vi) the CDRs of claim 1.vi) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 618; or vii) the CDRs of claim 1.vii) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 718; orAttorney Docket No.01245-0062-00PCT viii) the CDRs of claim 1.viii) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 818; or ix) the CDRs of claim 1.ix) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 918; or x) the CDRs of claim 1.x) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 1018; or xi) the CDRs of claim 1.xi) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 1118; or xii) the CDRs of claim 1.xii) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 1218; or xiii) the CDRs of claim 1.xiii) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 1318; or xiv) the CDRs of claim 1.xiv) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 1418; or xv) the CDRs of claim 1.xv) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 1518; or xvi) the CDRs of claim 1.xvi) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 1618; or xvii) the CDRs of claim 1.xvii) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 1718; or xviii) the CDRs of claim 1.xviii) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 1818.

7. The isolated antibody of any one of claims 1-6, wherein the antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein: i) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 12 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 18; or ii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 112 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 118; or iii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 212 and the VL is atAttorney Docket No.01245-0062-00PCT least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 218; or iv) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 312 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 318; or v) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 512 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 518; or vi) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 612 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 618; or vii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 712 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 718; or viii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 812 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 818; or ix) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 912 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 918; or x) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1012 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1018; or xi) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1112 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1118; orAttorney Docket No.01245-0062-00PCT xii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1212 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1218; or xiii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1312 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1318; or xiv) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1412 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1418; or xv) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1512 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1518; or xvi) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1612 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1618; or xvii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1712 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1718; or xviii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1812 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1818.

8. The isolated antibody of any one of claims 1-7, wherein the antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein: i) the VH comprises the amino acid sequence of SEQ ID NO: 12 and the VL comprises the amino acid sequence of SEQ ID NO: 18; or ii) the VH comprises the amino acid sequence of SEQ ID NO: 112 and the VL comprises the amino acid sequence of SEQ ID NO: 118; orAttorney Docket No.01245-0062-00PCT iii) the VH comprises the amino acid sequence of SEQ ID NO: 212 and the VL comprises the amino acid sequence of SEQ ID NO: 218; or iv) the VH comprises the amino acid sequence of SEQ ID NO: 312 and the VL comprises the amino acid sequence of SEQ ID NO: 318; or v) the VH comprises the amino acid sequence of SEQ ID NO: 512 and the VL comprises the amino acid sequence of SEQ ID NO: 518; or vi) the VH comprises the amino acid sequence of SEQ ID NO: 612 and the VL comprises the amino acid sequence of SEQ ID NO: 618; or vii) the VH comprises the amino acid sequence of SEQ ID NO: 712 and the VL comprises the amino acid sequence of SEQ ID NO: 718; or viii) the VH comprises the amino acid sequence of SEQ ID NO: 812 and the VL comprises the amino acid sequence of SEQ ID NO: 818; or ix) the VH comprises the amino acid sequence of SEQ ID NO: 912 and the VL comprises the amino acid sequence of SEQ ID NO: 918; or x) the VH comprises the amino acid sequence of SEQ ID NO: 1012 and the VL comprises the amino acid sequence of SEQ ID NO: 1018; or xi) the VH comprises the amino acid sequence of SEQ ID NO: 1112 and the VL comprises the amino acid sequence of SEQ ID NO: 1118; or xii) the VH comprises the amino acid sequence of SEQ ID NO: 1212 and the VL comprises the amino acid sequence of SEQ ID NO: 1218; or xiii) the VH comprises the amino acid sequence of SEQ ID NO: 1312 and the VL comprises the amino acid sequence of SEQ ID NO: 1318; or xiv) the VH comprises the amino acid sequence of SEQ ID NO: 1412 and the VL comprises the amino acid sequence of SEQ ID NO: 1418; or xv) the VH comprises the amino acid sequence of SEQ ID NO: 1512 and the VL comprises the amino acid sequence of SEQ ID NO: 1518; or xvi) the VH comprises the amino acid sequence of SEQ ID NO: 1612 and the VL comprises the amino acid sequence of SEQ ID NO: 1618; or xvii) the VH comprises the amino acid sequence of SEQ ID NO: 1712 and the VL comprises the amino acid sequence of SEQ ID NO: 1718; or xviii) the VH comprises the amino acid sequence of SEQ ID NO: 1812 and the VL comprises the amino acid sequence of SEQ ID NO: 1818.

9. An isolated antibody that binds human CD74, wherein the antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein:Attorney Docket No.01245-0062-00PCT i) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 12 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 18; or ii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 112 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 118; or iii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 212 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 218; or iv) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 312 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 318; or v) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 512 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 518; or vi) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 612 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 618; or vii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 712 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 718; or viii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 812 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 818; or ix) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 912 and the VL is atAttorney Docket No.01245-0062-00PCT least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 918; or x) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1012 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1018; or xi) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1112 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1118; or xii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1212 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1218; or xiii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1312 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1318; or xiv) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1412 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1418; or xv) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1512 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1518; or xvi) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1612 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1618; or xvii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1712 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1718; orAttorney Docket No.01245-0062-00PCT xviii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1812 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1818.

10. The isolated antibody of claim 9, wherein the antibody comprises: i) the VH and VL of claim 8.i) and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 2; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 3; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 4; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 5; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 6; or ii) the VH and VL of claim 8.ii) and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 101; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 102; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 103; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 104; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 105; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 106; or iii) the VH and VL of claim 8.iii) and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 201; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 202; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 203; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 204; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 205; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 206; or iv) the VH and VL of claim 8.iv) and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 301; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 302; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 303; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 304; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 305; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 306; or v) the VH and VL of claim 8.v) and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 501; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 502; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 503; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 504; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 505; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 506; orAttorney Docket No.01245-0062-00PCT vi) the VH and VL of claim 8.vi) and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 601; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 602; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 603; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 604; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 605; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 606; or vii) the VH and VL of claim 8.vii) and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 701; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 702; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 703; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 704; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 705; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 706; or viii) the VH and VL of claim 8.viii) and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 801; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 802; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 803; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 804; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 805; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 806; or ix) the VH and VL of claim 8.ix) and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 901; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 902; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 903; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 904; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 905; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 906; or x) the VH and VL of claim 8.x) and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1001; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1002; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1003; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1004; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1005; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1006; or xi) the VH and VL of claim 8.xi) and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1101; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1102; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1103; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO:Attorney Docket No.01245-0062-00PCT 1104; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1105; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1106; or xii) the VH and VL of claim 8.xii) and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1201; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1202; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1203; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1204; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1205; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1206; or xiii) the VH and VL of claim 8.xiii) and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1301; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1302; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1303; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1304; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1305; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1306; or xiv) the VH and VL of claim 8.xiv) and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1401; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1402; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1403; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1404; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1405; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1406; xv) or the VH and VL of claim 8.xv) and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1501; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1502; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1503; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1504; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1505; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1506; or xvi) the VH and VL of claim 8.xvi) and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1601; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1602; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1603; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1604; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1605; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1606; or xvii) the VH and VL of claim 8.xvii) and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1701; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1702; (c) HCDR3 comprising the amino acid sequenceAttorney Docket No.01245-0062-00PCT of SEQ ID NO: 1703; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1704; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1705; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1706; or xviii) the VH and VL of claim 8.xviii) and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1801; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1802; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1803; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1804; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1805; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1806.

11. The isolated antibody of claim 9 or claim 10, wherein the VH comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to an amino acid sequence chosen from any one of SEQ ID NOs: 12, 112, 212, 312, 512, 612, 712, 812, 912, 1012, 1112, 1212, 1312, 1412, 1512, 1612, 1712, or 1812.

12. The isolated antibody of any one of claims 9-11, wherein the VL comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and / or deletions compared to an amino acid sequence chosen from any one of SEQ ID NOs: 18, 118, 218, 318, 518, 618, 718, 818, 918, 1018, 1118, 1218, 1318, 1418, 1518, 1618, 1718, or 1818.

13. The isolated antibody of any one of the preceding claims, wherein the antibody is a monoclonal antibody.

14. The isolated antibody of any one of the preceding claims, wherein the antibody is an antibody fragment.

15. The isolated antibody of claim 14, wherein the fragment is a Fab, Fab’, Fv, scFv or (Fab’)2.

16. The isolated antibody of any one of claims 1-13, wherein the antibody is a full- length antibody.

17. The isolated antibody of any one of claims 1-13, wherein an Fc region of the antibody comprises IgG1, IgG2, IgG3, or IgG4.

18. The isolated antibody of any one of claims 1-13, wherein the antibody comprises a human IgG1 heavy chain constant region.

19. The isolated antibody of any one of claims 1-13, wherein the antibody comprises a human IgG4 heavy chain constant region.

20. The isolated antibody of claim 18, wherein the antibody comprises a mutant human IgG1 heavy chain constant region.Attorney Docket No.01245-0062-00PCT 21. The isolated antibody of claim 20, wherein the mutant IgG1 heavy chain constant region comprises a mutation selected from a substitution at L234, a substitution at L235, a substitution at P329, or a combination thereof, according to EU numbering.

22. The isolated antibody of claim 21, wherein the mutant IgG1 heavy chain constant region comprises an L234A substitution, an L234A substitution, and a P329A substitution or a combination thereof, according to EU numbering.

23. The isolated antibody of any one of claims 20-22, wherein the mutant IgG1 heavy chain constant region comprises a deletion of K447, according to EU numbering.

24. The isolated antibody of any one of claims 20-23, wherein the mutant IgG heavy chain constant region comprises a substitution at S239, according to EU numbering.

25. The isolated antibody of any one of claims 20-24, wherein the mutant IgG heavy chain constant region comprises an S239C substitution, according to EU numbering.

26. The isolated antibody of any one of claims 1-13 and 16-25, wherein the antibody comprises a human IgG kappa light chain constant region.

27. The isolated antibody of any one of claims 1-26, further comprising an effector molecule conjugated to the antibody.

28. The isolated antibody of claim 27, wherein the effector molecule comprises a cytotoxic agent.

29. The isolated antibody of claim 28, wherein the cytotoxic agent is selected from a DNA inhibitor, a topoisomerase inhibitor, or a tubulin inhibitor.

30. The isolated antibody of claim 28 or claim 29, wherein the cytotoxic agent is selected from Monoimine indolinobenzodiazepene (DGN549C), Tesirine, Talirine, Duocarmycin (secoDUBA prodrug), NMS249 (anthracycline), PNU (anthracycline), Dxd (exatecan), Monomethyl auristatin F (MMAF), Monomethyl auristatin E (MMAE), Ravtansine (DM4), and Pyrrolobenzodiazepine (PBD).

31. The isolated antibody of any one of claims 28-30, wherein the cytotoxic agent is DGN549C.

32. The isolated antibody of claim 31, wherein the DGN549C is conjugated to the antibody at an S239C substitution of a IgG heavy chain constant region.

33. A humanized or fully human version of the antibody of any one of the preceding claims.

34. A conjugate comprising an anti-CD74 antibody and an effector molecule conjugated to the antibody, the anti-CD74 antibody comprising: i) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1 with one or two aminoAttorney Docket No.01245-0062-00PCT acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 2 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 2 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 3 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 3 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 4 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 4 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 5 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 5 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 6 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 6 with one or two amino acid substitutions; or ii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 101 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 101 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 102 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 102 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 103 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 103 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 104 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 104 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 105 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 105 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 106 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 106 with one or two amino acid substitutions; or iii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 201 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 201 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 202 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 202 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 203 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 203 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 204 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 204 with one or two amino acidAttorney Docket No.01245-0062-00PCT substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 205 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 205 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 206 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 206 with one or two amino acid substitutions; iv) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 301 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 301 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 302 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 302 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 303 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 303 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 304 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 304 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 305 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 305 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 306 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 306 with one or two amino acid substitutions; or v) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 501 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 501 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 502 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 502 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 503 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 503 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 504 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 504 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 505 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 505 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 506 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 506 with one or two amino acid substitutions; or vi) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 601 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 601 with one or two aminoAttorney Docket No.01245-0062-00PCT acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 602 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 602 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 603 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 603 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 604 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 604 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 605 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 605 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 606 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 606 with one or two amino acid substitutions; or vii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 701 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 701 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 702 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 702 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 703 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 703 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 704 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 704 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 705 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 705 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 706 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 706 with one or two amino acid substitutions; or viii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 801 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 801 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 802 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 802 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 803 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 803 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 804 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 804 with one or two amino acidAttorney Docket No.01245-0062-00PCT substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 805 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 805 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 806 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 806 with one or two amino acid substitutions; or ix) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 901 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 901 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 902 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 902 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 903 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 903 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 904 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 904 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 905 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 905 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 906 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 906 with one or two amino acid substitutions; or x) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1001 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1001 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1002 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1002 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1003 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1003 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1004 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1004 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1005 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1005 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1006 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1006 with one or two amino acid substitutions; or xi) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1101 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1101 with one or two aminoAttorney Docket No.01245-0062-00PCT acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1102 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1102 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1103 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1103 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1104 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1104 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1105 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1105 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1106 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1106 with one or two amino acid substitutions; or xii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1201 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1201 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1202 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1202 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1203 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1203 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1204 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1204 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1205 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1205 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1206 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1206 with one or two amino acid substitutions; or xiii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1301 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1301 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1302 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1302 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1303 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1303 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1304 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1304 with one or two aminoAttorney Docket No.01245-0062-00PCT acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1305 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1305 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1306 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1306 with one or two amino acid substitutions; or xiv) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1401 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1401 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1402 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1402 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1403 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1403 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1404 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1404 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1405 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1405 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1406 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1406 with one or two amino acid substitutions; or xv) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1501 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1501 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1502 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1502 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1503 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1503 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1504 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1504 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1505 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1505 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1506 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1506 with one or two amino acid substitutions; or xvi) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1601 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1601 with one orAttorney Docket No.01245-0062-00PCT two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1602 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1602 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1603 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1603 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1604 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1604 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1605 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1605 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1606 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1606 with one or two amino acid substitutions; or xvii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1701 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1701 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1702 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1702 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1703 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1703 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1704 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1704 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1705 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1705 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1706 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1706 with one or two amino acid substitutions; or xviii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1801 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1801 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1802 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1802 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1803 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1803 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1804 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1804 with one or two aminoAttorney Docket No.01245-0062-00PCT acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1805 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1805 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1806 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1806 with one or two amino acid substitutions; or xix) a VH that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 12 and a VL that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 18; or xx) a VH that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 112 and a VL that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 118; or xxi) a VH that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 212 and a VL that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 218; or xxii) a VH that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 312 and a VL that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 318; or xxiii) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 512 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 518; or xxiv) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 612 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 618; or xxv) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 712 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 718; or xxvi) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 812 and a VL is atAttorney Docket No.01245-0062-00PCT least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 818; or xxvii) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 912 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 918; or xxviii) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1012 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1018; or xxix) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1112 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1118; or xxx) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1212 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1218; or xxxi) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1312 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1318; or xxxii) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1412 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1418; or xxxiii) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1512 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1518; or xxxiv) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1612 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1618; orAttorney Docket No.01245-0062-00PCT xxxv) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1712 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1718; or xxxvi) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1812 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1818.

35. The conjugate of claim 34, wherein the effector molecule comprises a cytotoxic agent.

36. The conjugate of claim 35, wherein the cytotoxic agent is selected from a DNA inhibitor, a topoisomerase inhibitor, or a tubulin inhibitor.

37. The conjugate of claim 35 or claim 36, wherein the cytotoxic agent is selected from Monoimine indolinobenzodiazepene (DGN549C), Tesirine, Talirine, Duocarmycin (secoDUBA prodrug), NMS249 (anthracycline), PNU (anthracycline), Dxd (exatecan), Monomethyl auristatin F (MMAF), Monomethyl auristatin E (MMAE), Ravtansine (DM4), and Pyrrolobenzodiazepine (PBD).

38. The conjugate of any one of claims 35-37, wherein the cytotoxic agent is DGN549C.

39. The conjugate of any one of claims 34-38, wherein the anti-CD74 antibody comprises the isolated antibody of any one of claims 1, 3-12 and 16-26.

40. A composition comprising the antibody of any one of claims 1-33 and a pharmaceutically acceptable carrier.

41. A method of conditioning a subject to reduce an endogenous population of hematopoietic stem cells in the subject comprising administering an anti-CD74 antibody to the subject, the anti-CD74 antibody comprising the isolated antibody of any one of claims 1-13 and 16-26.

42. The method of claim 41, wherein the anti-CD74 antibody is conjugated to an effector molecule.

43. The method of claim 42, wherein the effector molecule comprises a cytotoxic agent.

44. The method of claim 43, wherein the cytotoxic agent is selected from a DNA inhibitor, a topoisomerase inhibitor, or a tubulin inhibitor.

45. The method of claim 43 or claim 44, wherein the cytotoxic agent is selected from Monoimine indolinobenzodiazepene (DGN549C), Tesirine, Talirine, Duocarmycin (secoDUBAAttorney Docket No.01245-0062-00PCT prodrug), NMS249 (anthracycline), PNU (anthracycline), Dxd (exatecan), Monomethyl auristatin F (MMAF), Monomethyl auristatin E (MMAE), Ravtansine (DM4), and Pyrrolobenzodiazepine (PBD).

46. The method of any one of claims 43-45, wherein the cytotoxic agent is DGN549C.

47. The method of any one of claims 41-46, wherein the anti-CD74 antibody is internalized by the endogenous population of hematopoietic stem cells.

48. The method of any one of claims 41-47, wherein the anti-CD74 antibody comprises an effector silencing modification.

49. The method of any one of claims 41-48, wherein the hematopoietic stem cells are reduced in bone marrow.

50. The method of any one of claims 41-49, wherein the hematopoietic stem cells are CD34+ cells.

51. The method of any one of claims 41-50, wherein the hematopoietic stem cells are human cells.

52. The method of any one of claims 41-51, comprising administering a composition comprising cells following conditioning of the subject to reduce the endogenous population of hematopoietic stem cells.

53. The method of any one of claims 41-52, comprising administering to the subject a composition comprising CD34+ human hematopoietic stem and / or progenitor cells (hHSPCs).

54. The method of any one of claims 41-53, comprising administering a composition comprising CD34+ human hematopoietic stem and / or progenitor cells (hHSPCs) that comprise a genetic modification.

55. The method of any one of claims 41-54, wherein the subject has a hemoglobinopathy.

56. A nucleic acid encoding the antibody of any one of claims 1-26.

57. A host cell comprising the nucleic acid of claim 56.

58. A method of producing the antibody of any one of claims 1-26 comprising culturing the host cell of claim 57 under conditions wherein the antibody is expressed.

59. The method of claim 58, further comprising purifying the antibody.

Citation Information

Patent Citations

  • Bispecific and oligospecific, mono- and oligovalent receptors, production and applications thereof

    EP0404097A2

  • Conjugates of cysteine engineered antibodies

    US10898579B2

  • Process for purifying antibody

    US20020164328A1

  • Antibody composition-producing cell

    US20030115614A1

  • Glycoprotein compositions

    US20030157108A1